Community-based strategies to increase coverage of Intermittent Preventive Treatment in Pregnancy with Sulfadoxine-Pyrimethamine in sub-Saharan Africa: A systematic review, meta-analysis, meta-ethnography, and economic assessment

Kadiatou Koita^{1,2}, Kassoum Kayentao², Eve Worrall¹, Anna Maria Van Eijk^{1*} and Jenny Hill^{1*}

¹ Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom

² Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Mali

* Joint last authors

Supplementary appendix

List of tables and figures

Supplementary Table 1: Search terms and number of records by database1
Supplementary methods
Supplementary Table 2. Estimates of average number of participants per cluster for each (sub) study2
Supplementary results
Table 3: Intervention characteristics, chronologically4
Supplementary Figure 1: Risk of bias assessment of randomized controlled trials
Supplementary Figure 2: Risk of bias assessment of non-randomized studies9
Supplementary Figure 3: Forest plot of difference-in-differences by doses of IPTp in studies comparing IPTp with sulfadoxine-pyrimethamine provided by community health workers versus IPTp in the antenatal clinic only 10
Supplementary Table 4. Subgroup analyses, including sensitivity analyses, for effects of interventions on number of doses of IPTp
Supplementary Table 5. Meta-analyses for effect of interventions on number of doses of IPTp 15
Supplementary Figure 4: "Leave-one-out" forest plot for three or more doses or IPTp 16
Supplementary Figure 5: Funnel plot for three or more IPTp doses 17
Supplementary Figure 6: Forest plot of difference-in-differences for two randomized trials comparing c-IPTp versus no c-IPTp for number of ANC visits
Supplementary Table 6: Meta-analyses for effect of interventions on number of ANC visits
Supplementary Table 7: Subgroup analyses, including sensitivity analyses, for effects of interventions on four or more ANC visits
Supplementary Figure 7: "Leave-one-out" forest plot for four or more ANC visits
Supplementary Figure 8: Funnel plot for four or more ANC visits
Supplementary Table 8: Checklist for quality reporting: Mixed Methods Studies
Supplementary Table 9: Checklist for quality reporting: Qualitative studies
Supplementary Table 10: Themes related to barriers to community IPTp promotion or delivery
Supplementary Table 11: Themes related to facilitators of community IPTp delivery
Supplementary Table 12: Lists of records excluded and reasons for exclusion
References

Supplementary	Table 1	: Search	terms and	number	of records	by	database
---------------	---------	----------	-----------	--------	------------	----	----------

Database	Search terms	Result
PubMed	pregnant women OR provider* OR ANC service* OR community health worker* OR community health volunteer* OR community health relay* OR ANC nurse OR ANC midwife OR health worker AND intermittent preventive treatment* OR intermittent presumptive therap* OR intermittent protective treatment* OR ipt OR iptp* OR sulphadoxine pyrimethamine OR sulfadoxine OR sulfadoxine-pyrimethamine AND delivery OR administration OR distribution OR uptake* OR community deliver* OR outcome* OR strategy OR utilisation OR utilization OR coverage OR barrier* OR facilitator* OR compliance OR adherence OR attitude* OR belie* OR knowledge OR delivery effectiv* OR determinant* OR evaluat* OR delivery system* OR predictor* OR DOT OR directly observed OR behaviour* OR behavior* OR promotion*	958
Cochrane Library	pregnant women OR provider* OR ANC service* OR community health worker* OR community health volunteer* OR community health relay* OR ANC nurse OR ANC midwife OR health worker AND intermittent preventive treatment* OR intermittent presumptive therap* OR intermittent protective treatment* OR ipt OR iptp* OR sulphadoxine pyrimethamine OR sulfadoxine OR sulfadoxine-pyrimethamine AND delivery OR administration OR distribution OR uptake* OR community deliver* OR outcome* OR strategy OR utilisation OR utilization OR coverage OR barrier* OR facilitator* OR compliance OR adherence OR attitude* OR belie* OR knowledge OR delivery effectiv* OR determinant* OR evaluat* OR delivery system* OR predictor* OR DOT OR directly observed OR behaviour* OR behavior* OR promotion*	965
Malaria in Pregnancy Library	pregnant women OR provider* OR ANC service* OR community health worker* OR community health volunteer* OR community health relay* OR ANC nurse OR ANC midwife OR health worker AND intermittent preventive treatment* OR intermittent presumptive therap* OR intermittent protective treatment* OR ipt OR iptp* OR sulphadoxine pyrimethamine OR sulfadoxine OR sulfadoxine-pyrimethamine AND delivery OR administration OR distribution OR uptake* OR community deliver* OR outcome* OR strategy OR utilisation OR utilization OR coverage OR barrier* OR facilitator* OR compliance OR adherence OR attitude* OR belie* OR knowledge OR delivery effectiv* OR determinant* OR evaluat* OR delivery system* OR predictor* OR DOT OR directly observed OR behaviour* OR behavior* OR promotion*	1654
EBSCOhost (Medline, Global Health & GH Archive)	pregnant women OR provider* OR ANC service* OR community health worker* OR community health volunteer* OR community health relay* OR ANC nurse OR ANC midwife OR health worker AND intermittent preventive treatment* OR intermittent presumptive therap* OR intermittent protective treatment* OR ipt OR iptp* OR sulphadoxine pyrimethamine OR sulfadoxine OR sulfadoxine-pyrimethamine AND delivery OR administration OR distribution OR uptake* OR community deliver* OR outcome* OR strategy OR utilisation OR utilization OR coverage OR barrier* OR facilitator* OR compliance OR adherence OR attitude* OR belie* OR knowledge OR delivery effectiv* OR determinant* OR evaluat* OR delivery system* OR predictor* OR DOT OR directly observed OR behaviour* OR behavior* OR promotion*	1155
International Clinical Trials Registry Platform	(pregnant women OR provider* OR ANC service* OR community health worker* OR community health volunteer* OR community health relay* OR ANC nurse OR ANC midwife OR health worker) AND (intermittent preventive treatment* OR intermittent presumptive therap* OR intermittent protective treatment* OR ipt OR iptp* OR sulphadoxine pyrimethamine OR sulfadoxine OR sulfadoxine-pyrimethamine) AND (delivery OR administration OR distribution OR uptake* OR community deliver* OR outcome* OR strategy OR utilisation OR utilization OR coverage OR barrier* OR facilitator* OR compliance OR adherence OR attitude* OR belie* OR knowledge OR delivery effectiv* OR determinant* OR evaluat* OR delivery system* OR predictor* OR DOT OR directly observed OR behaviour* OR behavior* OR promotion*)	21

Supplementary methods

Data extraction

Assignment of study quality in categories

Each study was graded numerically by assigning a grade of 1 to 3 to each of the bias domains, with 1 being high or serious risk of bias, 2 being some concerns or moderate risk of bias, and 3 being low risk of bias. An overall score was tabulated for each study by dividing the sum of the grades from each domain by the number of domains. A study with a score under 1.5 was considered of poor quality, a study with a score between 1.6 and 2.4 of moderate quality, while a study with a score of 2.5 to 3 was considered of good quality.

We intended to combine summary estimates using meta-analysis, taking clustering into account, and using a random effects model, and to present results in forest plots. However, effect measures reported were diverse, and only four studies presented effect measures that could directly be combined (Difference-in-Differences results) using meta-analysis. Some studies were cluster-adjusted but data were not presented adjusted for clusters and others were not cluster adjusted but clusters such as villages and health centres were described. To adjust the studies for clustering using the design effects, we estimated the average number of participants per cluster to our best ability with information available from the articles (Supplementary table 2).

Study	Country	Cluster number	Total sample	Average cluster size
Gutman 2020 ¹	Burkina Faso	12 health facilities	360	30
Rubenstein 2022 ²	Malawi	20 health facilities	687	34.4
Cosmic 2018 ³	Benin	30 villages	971	32.4
Cosmic 2018 ³	Burkina Faso	30 villages	1762	60
Cosmic 2018 ³	Gambia	30 villages	1960	65.3
Gonzalez 20234*	DRC	NR	NR	13
Gonzalez 20234*	Madagascar	NR	NR	13
Gonzalez 2023 ⁴ *	Mozambique	NR	NR	13
Gonzalez 20234*	Nigeria	NR	NR	13
Gies 2009 ⁵	Burkina Faso	12 health facilities	2766	230.5
Okeibunor 20116	Nigeria	6 LGAs	1378	35.5
Wangalwa 2012 ⁷ †	Kenya	14 supervision strata	266	19
Msyamboza 20098	Malawi	26 villages	1809	69.6
Ndyomugyenyi 2009 ⁹ †	Uganda	79 villages	926	11.7
Mbonye 2007 ¹⁰	Uganda	25 parishes	2785	111.4
Orobaton 2016 ¹¹ †	Nigeria	42 wards	31493	749.8
Kayentao 2023 ¹² *	Mali	137 villages	5,112	37.3

Supplementary	Table 2. Es	stimates of averag	e number of r	participants r	per cluster for	each (sub) study
							//

LGA, local government area level. NR, not reported.

*Gonzalez et al (2023) reported that an average of 13 women per cluster were enrolled.⁴

†These studies did not report a cluster design. However, the description of the study made it likely that a cluster adjustment was warranted. *Reported cluster adjusted risk ratio. No design effect calculation was needed.

As an additional measure of heterogeneity, we used the prediction interval, which allows to quantify the extent of dispersion, or the range of effects, whereas the 95% confidence interval of the effect estimate is an indicator of precision. Note that all the measures of heterogeneity, such as I^2 and the prediction interval are not reliable when based on a small number of studies (< 10).

The WHO suggested that "Where inequities in ANC service and reach exist, other delivery methods (such as the use of community health workers) may be explored, ensuring that ANC attendance is maintained and underlying inequities in ANC delivery are addressed". To assess if CHW involvement in areas of low ANC coverage would result in better effects, we included, as additional subgroup analysis, information on baseline or control arm ANC coverage. High ANC4+ was defined as coverage of \geq 50% (the mean number of ANC visits across sub-Saharan Africa has been reported as $3 \cdot 8$).¹³ Gonzalez et al. suggested that baseline IPTp coverage may affect the intervention result.⁴ To examine this further we added a subgroup analysis by baseline coverage of IPTp. High IPTp2+ was defined as a baseline or

control arm coverage of $\geq 60\%$, the first target for coverage, and high IPTp3+ as baseline or control arm coverage of $\geq 40\%$. The cutoffs were based on old guidelines for IPTp2+ coverage and for IPTp3+ on the variability of the data.¹⁴

Supplementary results Table 3: Intervention characteristics, chronologically

Study	Objective	Intervention	Duration	1st SP	Pre-	Gender	Selection	Training of	Trainers	Payment	Supervision	Identification	CHW-	Community
Author, year		strategy		dose in ANC?	existing CHWs	Of CHWs	criteria of CHWs	CHWs	of CHWs	to CHWs or	of CHWs	pregnant women	PW ratio	sensitization
					in health system?					incentives				
Mbonye, 2007 ^{10,15}	Assess the impact of c- IPTp-SP on access and compliance	Community resource persons* delivered IPTp- SP and other health services to PW. Home visits by CHWs and encouragement of involvement of spouses	17 months	No	Yes	Male Female	Pre-existing traditional birth attendants, adolescents peer mobilizers, community reproductive health workers, and drug shop vendors were identified and trained.	1-week training on the dangers of MiP, malaria prevention in pregnancy, benefits of SP and side effects; blood samples collection, measuring baby's weight and estimating GA	NR	Bicycles for transportati on	Field supervisor, laboratory assistant and the principal investigator	Enrolment of PW through creating awareness. Women were recruited when they came and sought care/medication from CHWs and through CHWs' home visits	NR	A community mobilization and sensitization campaign was conducted to ensure that all women received information on the intervention and where to get SP
Gies, 2009 ⁵	Evaluate the effect of a promotional campaign for women on ANC use and IPTp-SP coverage	Women field assistants screened, recruited women in their first or second pregnancy during monthly village visits, and referred them to ANC and followed up with 2 visits	24 months	Yes	No	Female	Female leaders selected with the agreement of community representatives. Selection from all sub-villages to cover the variety of local ethnic groups and languages between these villages	2-day training courses on all relevant aspects of ANCs and IPTp-SP, and on the use of the image boxes, animation techniques for individuals, and group discussions	Social scientist	NR	Social scientist	Identification and recruitment of PW done by the CHWs during the monthly village visits	NR	Twice-a- month sensitization sessions on malaria, ANC and IPTp by the selected women leaders. Health Market Days
Msyamboza, 2009 ⁸	Assess the impact of c- IPTp on uptake	Community promotion of ANC and delivery of IPTp-SP by CHWs	24 months	No	No	Female	Women who taught AGLIT curriculum were selected and acted as CHWs in their respective villages. If there was no female teacher, another literate woman was chosen by the village	Training on data collection, how to encourage PW in their villages to attend ANC at their respective hospitals, how to measure birth weight, and fundal height	NR	NR	NR	Women either voluntarily approached CHWs for enrolment in the study or were actively sought out by the CHWs	l CHW per village	Community awareness meetings were held in all selected villages. Meetings were conducted every 3 months in each village to identify challenges and issues

Ndyomugyenyi, 2009 ⁹	Evaluate the impact of c- IPTp on uptake	Community promotion of ANC and promotion and delivery of IPTp by community drug distributors	12 months	No	Yes	NR	CHWs from the onchocerciasis control programme	2-day training on the dangers of malaria to both the mother and foetus and on how to administer IPTp-SP by DOT	NR	NR	Health facility workers	Pregnant women went to the CHWs' homes, or to the health facility	NR	Health education on malaria and its dangers for mother and foetus through participatory community meetings at a central level in villages
Okeibunor, 2011 ⁶	Increase access to malaria prevention (IPT/ITN) among PW	CHWs delivered ITNs and SP (IPTp1 and IPTp2) to PW, provided basic health counselling services, referred PW to HF for additional ANC services	30 months	No	No	Female	The selection of CHWs delegated to each kindred, extended family units or clans with a common ancestry, within a given community. Priority given to women with prior childbearing experience	Training on how to deliver ITNs and SP to PW, and how to provide basic health counselling services, and ANC promotion	Staff of the nearest health facility	NR	Staff of the nearest health facility	CHWs identified PW in the community	1 CHW per 23 births per calendar year	Community stakeholders' engagement and sensitization by health workers in local meetings
Wangalwa, 2012 ⁷	Evaluate the effectiveness of community- based delivery of maternal and newborn care intervention on adoption of services	Community promotion of ANC and delivery of other maternal and newborn care	22 months	Yes	Yes	NR	Elections during meetings convened by the respective village elders. Eligibility criteria include ability to read and write, permanent residence in the community and demonstrated commitment to the service of their neighbours	7-day training on community- maternal and newborn care	Communit y health extension workers	NR	Community health extension workers	CHWs identified PW in the community.	2 per village	Meetings with community health committee, including an average of 12 elected members by the community
Orobaton, 2016 ¹¹	Examine scale up mechanisms enabling SP uptake, community acceptance,	Community promotion of ANC and promotion and delivery of IPTp-SP by CHWs in addition to	8 months	No	Yes	NR	Built in the health system	Training on WHO prescribed counselling messages, SP delivery, identification of adverse events.	NR	NR	Facility health worker	Household mapping and enumeration of WRA and PW	15 CHWs per ward, 6-10 per 10,000 residents	Bi-monthly meeting with Legal Government Area level stakeholders

	and delivery cost	promotion of HF delivery												
COSMIC Consortium, 2018 ³ Burkina Faso	Assess the impact of the addition of CSST to standard IPTp-SP on	CHWs visited women in their houses monthly, screened and treated them if	24 months	Yes	Yes	Male Female	NR	CHWs in the intervention arm were trained in malaria case management and MiP,	NR	NR	NR	Recruitment was done at 1 st ANC visit, and continuous identification of PW in the	NR	Community sensitization and involvement of community leaders,
Gambia	infant health.	and encouraged them to attend		Yes	Yes			benefit of early ANC attendance and IPTp-SP				CHWs		community meetings
Benin				Yes	Yes			und if Tp br						
Gutman, 2020 ¹	Assess the effect of c- IPTp-SP on coverage	CHWs delivered IPTp- SP to women and promoted ANC attendance.	15 months	Yes	Yes	Male Female	Female volunteers recruited from the community to complete pairs of existing male and female CHWs so that only females conducted home visits for cultural purposes.	2-day training focused on mastery of data collection tools, ethical rules, potential adverse events related to SP administration	Health facility workers	US \$35 per month	Health facility workers	PW recruited from the health facilities during the ANC visits and referred to CHWs	1 CHW per 20 PW	NR
Rubenstein, 2022 ²	Assess the effect of c- IPTp on coverage	Community promotion of ANC and promotion and delivery of IPTp-SP by CHWs	21 months	Yes	Yes	Male Female	CHWs are the lowest cadre of service providers within the MoH; plus volunteers called Secret Mothers.	3-day training on how to provide follow- up IPTp to PW, community- based maternal and newborn health, record- keeping for the study registers and ANC cards.	NR	NR	Study personnel	CHWs worked with community leaders, supervisors and health facility staff to identify PW.	1 CHW per 140 PW	Collaboration with NGOs; 1- day education for the Area Development Committees
Gonzalez 2023 ⁴	Assess the effect of c- IPTp-SP on coverage	CHWs delivered IPTp- SP to women and promoted ANC	18 months- 30 months			NR	NR	CHWs were trained to identify PW in the community, to	NR	NR	NR	Identification and recruitment of pregnant women done by the CHWs in		NR
DRC		attendance.		Yes	Yes			screen them for eligibility to receive				the community	1 CHW per 20 PW	
Madagascar				No	Yes			IPTp-SP, to deliver IPTp per the WHO					1 CHW per 28 PW	
Mozambique				No	Yes			guidelines, and to refer women to ANC					1 CHW per 207 PW	

Nigeria				Yes	Yes								1 CHW per 43 PW	
Kayentao 2023 ¹²	Assess whether proactive pregnancy detection by CHWs will increase ANC indicators	Trained CHWs went door to door to identify PW, deliver ANC and other services and refer PW to HF	24 months- 36 months	Yes	Yes	Male Female	Local community members— female candidates encouraged— who can read and write in French	CHWs trained to proactively identify PW and provide a comprehensive package of primary health care services	NR	40,000 Fcfa (about \$80 US) per month	NR	Proactive identification of PW by CHWs in the community through administration of pregnancy test	1 CHW per 700 populatio n	Community consultation and meetings with community leaders and women's and youth associations

Abbreviations: AGLIT, an adolescent girls literacy project. ANC, antenatal clinic. CHW, community health worker. c-IPTp, intermittent preventive treatment delivered by community health workers. CSST, Community-based Scheduled Screening and Testing. DOT, directly observed treatment. GA: gestational age. HF, health facility. ITN, insecticide treated net. MiP: malaria in pregnancy; NR: not reported. PW, pregnant women. RDT, rapid diagnostic malaria test. WHO, World Health Organization. WRA: Women of reproductive age.

*Community resource persons include traditional health attendants (TBAs), community reproductive health workers (CRHWs), adolescent peer mobilizers (APMs), and drug-shop vendors (DSVs).

				RISK C	o bias do	mains			
		D1	D1b	D2	D3	D4	D5	5	Overall
	COSMIC Consortium 2018	-	+	+	+	-	+		+
	Gies 2009	X	-	+	+	+	-		-
Study	Gutman 2020	+	+	+	+	+	+		+
•	Rubenstein 2022	+	+	+	+	-	+		+
	Kayentao 2023	-	+	-	+	-	+		-
		Domains:					Judg	jeme	nt
		D1 : Bias	arising fro arising fro	m the rand m the timin	omization p a of identif	process.	X	Higł	h
		and	recruitment	of Individu	ual participa nization.	ants in	•	Son	ne concerns
		D2 : Bias D3 : Bias D4 : Bias D5 : Bias	due to dev due to mis in measur in selectio	viations from ssing outco ement of th n of the rep	m intended me data. ne outcome ported resu	interventior It.	ı. 🛨	Low	1

Supplementary Figure 1: Risk of bias assessment of randomized controlled trials Bisk of bias domains

The majority of the randomized controlled trials were graded good quality, with risks of bias ranging from low to some concerns. Only two of the five RCTs were graded as having some concerns mostly due to a risk of bias in the randomization process.

Supplementary Figure 2: Risk of bias assessment of non-randomized studies

Five out of the seven non-randomized studies, however, were graded low in quality mostly due to high risk of confounding bias, and outcome measurement bias. Only one non-randomized study was graded as good quality with a low risk of bias.



D7: Bias in selection of the reported result.

			Ν								
Ν	Control		Intervention		N Control		N	Event		Effect	%
Outcome and Study, Country	before	%	before	%	after	%	Intervention	%		(95% CI)	Weight
		З									
IPTp 1+											
Rubenstein 2022 Malawi	188	92.9	182	83.0	344	89.8	343	93.3		0.14 (0.05, 0.22)	88.66
Gutman 2020 Burkina Faso	186	86.2	188	80.7	180	75.6	180	86.1	++	0.16 (-0.09, 0.41)	11.34
Subgroup, DL (l ² = 0.0%, p = 0.845)									\$	0.14 (0.06, 0.22)	100.00
IPTp 2+											
Gutman 2020 Burkina Faso	186	73.4	188	69.9	180	64.4	180	72.2	 +	0.11 (-0.28, 0.50)	11.28
Rubenstein 2022 Malawi	188	70.0	182	71.3	344	82.2	343	81.0	-	-0.03 (-0.16, 0.11)	88.72
Subgroup, DL ($l^2 = 0.0\%$, p = 0.512)									\diamond	-0.01 (-0.14, 0.12)	100.00
IPTp 3+											
Rubenstein 2022 Malawi	188	45.6	182	45.1	344	59.8	343	66.0		0.07 (-0.06, 0.20)	17.09
Gutman 2020 Burkina Faso	186	54.3	188	50.5	180	47.2	180	61.1		0.18 (-0.16, 0.52)	13.86
Gonzalez 2023 DRC	323	23.5	432	21.8	556	23.9	420	61.9		0.39 (0.27, 0.51)	17.16
Gonzalez 2023 Madagascar	284	12.0	288	23.3	336	19.1	576	57.1		0.26 (0.13, 0.38)	17.11
Gonzalez 2023 Mozambique	480	34.6	720	63.3	684	45.0	767	58.0	+	-0.16 (-0.25, -0.06) 17.38
Gonzalez 2023 Nigeria	288	16.3	739	11.2	441	10.2	501	68.1	↓ +	0.62 (0.53, 0.72)	17.38
Subgroup, DL (I ² = 96.5%, p <0.000	1)									0.23 (-0.04, 0.50)	100.00
IPTp 4+											
Gutman 2020 Burkina Faso	186	16.0	188	21.5	180	21.1	180	46.7	_ <u>+</u> +	0.20 (-0.07, 0.47)	36.54
Rubenstein 2022 Malawi	188	16.2	182	15.4	344	25.8	343	24.5	 +	-0.01 (-0.18, 0.17)	63.46
Subgroup, DL (l ² = 34.9%, p = 0.215)								\Leftrightarrow	0.07 (-0.12, 0.26)	100.00
								Ţ		ļ	
								-1		1	
								Favo	urs no ciPip Favours ciPip		

Supplementary Figure 3: Forest plot of difference-in-differences by doses of IPTp in studies comparing IPTp with sulfadoxine-pyrimethamine provided by community health workers versus IPTp in the antenatal clinic only

Abbreviation: CI, confidence interval. DL, DerSimonian and Laird (method). DRC, Democratic Republic of Congo. IPTp, intermittent preventive treatment in pregnancy.

	N Sub- No cluster adjustment* studies					e of 0.0	2 used*	ICC estimate of 0.06 used*			ICC estimate	of 0.09	used*	ICC estimate of 0.20 used*		
Subgroup analyses		Pooled RR, 95% CI	<i>I</i> ² , %	p†	Pooled RR, 95% CI	<i>I</i> ² , %	p†	Pooled RR, 95% CI	<i>I</i> ² , %	p†	Pooled RR, 95% CI	<i>I</i> ² , %	p†	Pooled RR, 95% CI	I ² , %	p†
IPTp2+																
Intervention																
type																
c-IPTp	8	1·88, 1·18- 3·00	99.5	0.18	1.86, 1.37-2.51	96.7	0.17	1.81, 1.37-2.40	93.1	0.16	1.78, 1.34-2.36	91.1	0.18	1.69, 1.28-2.23	83.1	0.12
ANC prom/c- IST	3	1.02, 0.99- 1.06	0.0		1.02, 0.99-1.06	0.0		1.02, 0.99-1.06	0.0		1.02, 0.99-1.06	0.0		1.02, 0.99-1.06	0.0	
ANC prom	1	1·44, 1·11- 1·69	-		1.44, 1.11-1.69	-		1.44, 1.11-1.69	-		1.44, 1.11-1.69	-		1.44, 1.11-1.69	-	
CHW home	0	-	-		-	-		-	-		-	-		-	-	
visits																
c-IPTp vs no c- IPTp																
c-IPTp	8	1·88, 1·18- 3·00	99.5	0.0773	1.86, 1.37-2.51	96.7	0.0744	1.81, 1.37-2.40	93.1	0.0713	1.78, 1.34-2.36	91.1	0.0794	1.69, 1.28-2.23	83.1	0.0771
No c-IPTp	4	1.05, 0.95- 1.17	74.0		1.05, 0.95-1.17	74.0		1.05, 0.95-1.17	74.0		1.05, 0.95-1.17	74.0		1.05, 0.95-1.17	74.0	
First dose in ANC																
Yes	7	1·11, 1·00- 1·23	84.7	0.0226	1.10, 0.99-1.22	80.7	0.0220	1.09, 0.98-1.20	75.4	0.0190	1.07, 0.97-1.18	72.5	0.0153	1.06, 0.97-1.17	66.3	0.0039
No	5	2·25, 1·32- 3·86	99.4		2.21, 1.64-2.98	94.8		2.12, 1.62-2.76	86.7		2.07, 1.59-2.71	81.5		1.96, 1.53-2.51	58.2	
First dose in ANC																
Yes & c-IPTp	3	1·32, 0·95- 1·82	92.7	0.0685	1.34, 0.87-2.06	89.7	0.0679	1.31, 0.89-1.92	84.0	0.0619	1.26, 0.87-1.82	80.4	0.0580	1.18, 0.85-1.64	67.0	0.0242
No & c-IPTp	5	2·25, 1·32- 3·86	99.4		2.21, 1.64-2.98	94.8		2.12, 1.62-2.76	86.7		2.07, 1.59-2.71	81.5		1.96, 1.53-2.51	58.2	
No c-IPTp	4	1·05, 0·95- 1·17	74.0		1.05, 0.95-1.17	74.0		1.05, 0.95-1.17	74.0		1.05, 0.95-1.17	74.0		1.05, 0.95-1.17	74.0	
First dose in ANC (c-IPTp																
Yes & c-IPTp	3	1.32, 0.95-	92.7	0.22	1.34, 0.87-2.06	89.7	0.22	1.31, 0.89-1.92	84.0	0.21	1.26, 0.87-1.82	80.4	0.19	1.18, 0.85-1.64	67.0	0.10
No & c-IPTp	5	2·25, 1·32- 3·86	99.4		2.21, 1.64-2.98	94.8		2.12, 1.62-2.76	86.7		2.07, 1.59-2.71	81.5		1.96, 1.53-2.51	58.2	
ANC4+ baseline																

Supplementary Table 4. Subgroup analyses, including sensitivity analyses, for effects of interventions on number of doses of IPTp

<50%	0	1.71 1.07	00.6	0.22	1.67 1.20 2.17	07.6	0.24	1.60 1.20 2.00	05.8	0.26	1.55 1.26 1.01	04.6	0.27	1.42 1.10 1.71	01.0	0.41
~30%	9	2·73	99.0	0.33	1.07, 1.29-2.17	97.0	0.24	1.00, 1.29-2.00	93.8	0.30	1.55, 1.20-1.91	94.0	0.37	1.42, 1.19-1.71	91.0	0.41
≥50%	3	1·21, 0·87- 1·67	97.3		1.21, 0.85-1.71	94.5		1.21, 0.89-1.64	88.0		1.20, 0.88-1.63	85.2		1.18, 0.90-1.54	69.7	
IPTp2+																
baseline																
<60%	8	1·81, 1·11- 2·96	99.4	0.18	1.78, 1.31-2.42	96.9	0.18	1.73, 1.30-2.29	95.1	0.19	1.69, 1.28-2.23	94.0	0.19	1.58, 1.22-2.06	90.8	0.23
≥60%	4	1·18, 0·95- 1·45	96.9		1.16, 0.97-1.38	90.7		1.13, 0.97-1.31	78.1		1.10, 0.95-1.27	69.8		1.07, 0.94-1.22	47.3	
IPTp3+ baseline																
<40%	6	2·02, 1·10- 3·71	99.3	0.0585	1.99, 1.30-3.05	96.7	0.0594	1.94, 1.30-2.90	94.2	0.0618	1.92, 1.29-2.86	92.9	0.0638	1.79, 1.23-2.62	88.6	0.0737
≥40%	4	1.02, 0.99- 1.05	1.7		1.02, 0.99-1.05	0.0		1.03, 1.00-1.06	0.0		1.03, 0.99-1.06	0.0		1.03, 1.00-1.06	0.0	
Design				1												1
QE-parallel	5	2·25, 1·32- 3·86	99.4	0.0165	2.21, 1.64-2.98	94.8	0.0128	2.12, 1.62-2.76	86.7	0.0121	2.07, 1.59-2.71	81.5	0.0105	1.96, 1.53-2.51	58.2	0.0042
Before-After	1	2·45, 1·74- 3·45	-		2.43, 1.64-3.62	-		2.47, 1.51-4.03	-		2.42, 1.40-4.19	-		2.43, 1.19-4.96	-	
Cluster-RCT	6	1·04, 0·97- 1·11	65.2		1.04, 0.96-1.11	61.4		1.04, 0.97-1.12	59.1		1.04, 0.96-1.12	60.3		1.04, 0.96-1.13	59.3	
Quality assessment																
Moderate	5	1·66, 1·53- 1·81	53.5	0.58	1.66, 1.51-1.81	35.8	0.56	1.65, 1.49-1.82	17.8	0.20	1.64, 1.50-1.80	0.0	0.47	1.63, 1.45-1.83	0.0	0.24
Good	7	1·45, 0·84- 2·50	99.7		1.42, 1.11-1.82	97.4		1.32, 1.09-1.60	94.0		1.26, 1.05-1.50	91.8		1.13, 0.98-1.30	83.3	
IPTp3+														\$		
Intervention																
type																
c-IPTp	6	2·14, 1·27- 3·63	99.0	0.37	2.14, 1.22-3.75	98.8	0.38	2.13, 1.21-3.76	98.3	0.39	2.13, 1.21-3.76	97.9	0.39	2.12, 1.21-3.73	96.7	0.49
ANC prom/c- IST	3	1·15, 0·88- 1·51	28.7		1.11, 0.96-1.27	0.0		1.10, 0.91-1.34	0.0		1.11, 0.88-1.39	0.0		1.10, 0.79-1.53	0.0	
ANC prom	0	-	-		-	-		-	-		-	-		-	-	
CHW home visits	1	1·06, 0·97- 1·15	-		1.06, 0.97-1.15	-		1.06, 0.97-1.15	-		1.06, 0.97-1.15	-		1.06, 0.97-1.15	-	
c-IPTp vs no c- IPTp																
c-IPTp	6	2·14, 1·27- 3·63	99.0	0.12	2.14, 1.22-3.75	98.8	0.15	2.13, 1.21-3.76	98.3	0.16	2.13, 1.21-3.76	97.9	0.16	2.12, 1.21-3.73	96.7	0.22
No c-IPTp	4	1·08, 1·01- 1·16	9.3		1.07, 1.00-1.15	0.0		1.07, 0.99-1.15	0.0		1.07, 0.98-1.15	0.0		1.06, 0.98-1.15	0.0	
First dose in ANC																
Yes	8	1·60, 1·06- 2·41	98.3	0.57	1.59, 1.01-2.52	97.9	0.57	1.60, 0.99-2.58	97.2	0.59	1.60, 0.99-2.60	96.7	0.59	1.66, 1.01-2.74	95.6	0.66

No	2	2·18, 0·60- 7·98	99.5		2.19, 0.60-8.03	99.3		2.17, 0.60-7.92	99.1		2.17, 0.60-7.85	98.9		2.16, 0.60-7.80	98.2	
First dose in ANC																
Yes & c-IPTp	4	2·13, 1·06- 4·27	98.9	0.37	2.11, 1.02-4.37	98.4	0.38	2.12, 1.05-4.26	97.5	0.39	2.11, 1.06-4.21	96.8	0.39	2.11, 1.06-4.19	95.0	0.50
No & c-IPTp	2	2·18, 0·60- 7·98	99.5		2.19, 0.60-8.03	99.3		2.17, 0.60-7.92	99.1		2.17, 0.60-7.85	98.9		2.16, 0.60-7.80	98.2	
No c-IPTp	4	1·08, 1·01- 1·16	9.3		1.07, 1.00-1.15	0.0		1.07, 0.99-1.15	0.0		1.07, 0.98-1.15	0.0		1.06, 0.98-1.15	0.0	
First dose in ANC (c-IPTp studies only)																
Yes & c-IPTp	4	2·13, 1·06- 4·27	98.9	0.97	2.11, 1.02-4.37	98.4	0.96	2.12, 1.05-4.26	97.5	0.97	2.11, 1.06-4.21	96.8	0.97	2.11, 1.06-4.19	95.0	0.98
No & c-IPTp	2	2·18, 0·60- 7·98	99.5		2.19, 0.60-8.03	99.3		2.17, 0.60-7.92	99.1		2.17, 0.60-7.85	98.9		2.16, 0.60-7.80	98.2	
ANC4+ baseline																
<50%	5	1·41, 0·89- 2·25	97.6	0.41	1.42, 0.85-2.36	97.1	0.43	1.42, 0.81-2.47	96.1	0.44	1.41, 0.80-2.51	95.4	0.45	1.49, 0.80-2.75	94.6	0.56
≥50%	5	2·02, 1·12- 3·64	99.1		2.01, 1.05-3.85	98.8		2.00, 1.03-3.88	98.4		2.00, 1.03-3.89	98.0		1.99, 1.03-3.83	96.8	
IPTp2+ baseline																
<60%	7	2·04, 1·21- 3·43	98.9	0.23	2.08, 1.24-3.49	98.7	0.19	2.11, 1.27-3.51	98.3	0.18	2.12, 1.28-3.51	98.0	0.18	2.25, 1.36-3.70	97.4	0.16
≥60%	3	1·13, 1·04- 1·22	15.9		1.10, 1.00-1.22	0.0		1.12, 0.98-1.27	0.0		1.13, 0.97-1.31	0.0		1.13, 0.93-1.37	0.0	
IPTp3+ baseline																
<40%	6	2·17, 1·23- 3·82	99.1	0.19	2.22, 1.27-3.86	98.9	0.12	2.21, 1.29-3.78	98.6	0.16	2.21, 1.20-3.74	98.3	0.16	2.31, 1.38-3.87	97.9	0.12
≥40%	4	1·13, 1·05- 1·22	12.7		1.11, 1.01-1.22	0.0		1.12, 0.98-1.28	0.0		1.13, 0.97-1.31	0.0		1.13, 0.93-1.38	0.0	
Design																
QE-parallel	0	-	-		-	-		-	-		-	-		-	-	<u> </u>
Before-After	4	2·87, 1·30- 6·37	99•4	0.0185	2.87, 1.29-6.37	99.2	0.0174	2.86, 1.29-6.33	98.9	0.0193	2.85, 1.29-6.30	98.7	0.0204	2.85, 1.29-6.33	97.9	0.0298
Cluster-RCT	6	1·11, 1·04- 1·18	20.3		1.08, 1.01-1.15	0.0		1.08, 1.00-1.16	0.0		1.08, 1.00-1.16	0.0		1.07, 0.99-1.16	0.0	
Quality assessment																
Moderate-to- low	4	2·87, 1·30- 6·37	99.4	0.0185	2.87, 1.30-6.37	99.2	0.0174	2.86, 1.29-6.33	98.9	0.0193	2.85, 1.29-6.30	98.7	0.0204	2.85, 1.29-6.33	97.9	0.0298
Good	6	1·11, 1·04- 1·18	20.3		1.08, 1.01-1.15	0.0		1.08, 1.00-1.16	0.0		1.08, 1.00-1.16	0.0		1.07, 0.99-1.16	0.0	

Abbreviations: ANC: antenatal clinic. Before-after: study design where an intervention is implemented and compared with a baseline survey. cIST: intermittent screening and testing for malaria by community health workers. c-IPTp: intermittent preventive treatment provided by community health workers (as opposed to ANC only). CHW: community health workers. ICC; intracluster correlation coefficient. IPTp: intermittent

preventive treatment in pregnancy. QE-parallel: quasi-experimental study with parallel design (control and intervention group measured at the same time). RCT: randomized controlled trial. ANC prom: intervention by CHWs to promote ANC attendance and IPTp coverage. In **bold effect estimates with a p-value of** <0.05.

*No cluster adjustment for studies for which adjusted risk ratios or odds ratios were not available. For studies which had an adjusted risk ratio or odds ratio available, this was always used in meta-analysis. The cluster adjustment involved the following studies: Mbonye 2007 Uganda,^{10,15} Msyamboza 2009 Uganda,⁸ Ndyomugyenyi 2009 Uganda,⁹ Okeibunor 2011 Nigeria,⁶ Orobaton 2016 Nigeria,¹¹ Rubenstein 2022 Malawi,² Wangalwa 2012 Kenya.⁷ For Gutman 2020 Burkina Faso, an ICC of 0.09 was used for all calculations, because that was the ICC they reported.¹

[†]P-value for the subgroup analysis, obtained by meta-regression

‡ For IPTp3+ and an ICC estimate of 0.20 one sub-study could not be included because of 0 values in prevalence estimates

	N sub- studies	No cluster adjustmer	nt*	ICC estimate of 0.02 used*		ICC estimate of 0.06 used*		ICC estimate of 0.09 u	sed*	ICC estimate of 0.20 used*	
Outcome IPTp		Pooled RR, 95% CI and 95% prediction interval	<i>I</i> ² , %	Pooled RR, 95% CI and 95% prediction interval	<i>I</i> ² , %	Pooled RR, 95% CI and 95% prediction interval	<i>I</i> ² , %	Pooled RR, 95% CI and 95% prediction interval	<i>I</i> ² , %	Pooled RR, 95% CI and 95% prediction interval	I ² , %
IPTp1+	7	1.25, 1.17-1.33 0.99-1.58	99.8	1.07, 1.04-1.11 0.96-1.19	97.6	1.05, 1.01-1.09 0.94-1.18	94.0	1.05, 1.00-1.09 0.91-1.20	91.9	1.04, 0.99-1.10 0.89-1.22	82.6
IPTp2+	12	1·56, 1·11-2·21 0·38-6·37	99.5	1·53, 1·26-1·87 0·71-3·32	97.1	1·48, 1·24-1·75 0·77-2·84	94.7	1·44, 1·22-1·69 0·78-2·65	93.2	1·34, 1·16-1·56 0·81-2·24	88.5
IPTp3+	10	1·71, 1·22-2·41 0·49-6·04	98.5	1·72, 1·19-2·48 0·45-6·50	98.2	1.73, 1.19-2.50 0.46-6.50	97.5	1·73, 1·20-2·50 0·47-6·42	97.0	1·77, 1·23-2·54 † 0·49-6·45	95.8
IPTp4+	4	1·33, 0·83-2·15 0·18-10·01	82.5	1·20, 0·86-1·68 0·36-1·68	45.0	1·23, 0·83-1·80† 0·02 to 73·6	56.5	1·25, 0·84-1·84† 0·02-75·2	52.9	1·27, 0·83-1·95† 0·02-107·19	50.6
IPTp5+	2	2.93, 0.18-47.08	95.9	2.73, 0.15-49.06	86.9	2.75, 0.15-50.70	85.9	2.81, 0.15-51.33	84.7	2.98, 0.17-52.19	81.7
Without study of Oroba	ton 2016										
IPTp1+	6	1.01, 1.00-1.02	89.6	1.01, 0.99-1.02	86.2	1.02, 0.99-1.04	79.9	1.02, 0.99-1.05	78.4	1.02, 0.99-1.06	58.4
IPTp2+	11	1.39, 1.16-1.65	97.5	1.38, 1.16-1.63	96.0	1.36, 1.16-1.59	93.8	1.34, 1.15-1.56	92.4	1.29, 1.12-1.48	87.7

Supplementary Table 5. Meta-analyses for effect of interventions on number of doses of IPTp

Abbreviations: ICC; intracluster correlation coefficient. IPTp: intermittent preventive treatment in pregnancy. RR: risk ratio

*No cluster adjustment for studies for which adjusted risk ratios or odds ratios were not available. For studies which had an adjusted risk ratio or odds ratio available, this was always used in meta-analysis. †One sub-study was not included because of 0 values.

Influence of individual sub-studies on pooled estimate for IPTp3+ and funnel plot

A "leave-one-out" forest plot showing the effect when each study is removed on the pooled IPTp3+ coverage is presented in Supplementary Figure 4. Effects of three sub-studies (Gonzalez 2023 in DRC, Madagascar and Nigeria) contributed relatively more than all others.⁴ Publication and small study effect biases were assessed for IPTp3+ using Egger's test and visual inspection of the funnel plot (Supplement Figure 5). There was no clear indication of asymmetry, but the number of sub-studies was low (Egger's test p= 0.35).

11 50		1		1
Study, Country omitted	Design	Intervention		Risk Ratio†
				(95% CI)
Cosmic 2018 Benin	Cluster-RCT	ANC prom/cIST		1.77 (1.22, 2.56)
Kayentao 2023 Mali	Cluster-RCT	CHW home visits	+ + +	1.82 (1.15, 2.89)
Rubenstein 2022 Malawi	Cluster-RCT	cIPTp		1.83 (1.21, 2.75)
Cosmic 2018 Burkina Faso	Cluster-RCT	ANC prom/cIST		1.83 (1.21, 2.75)
Gonzalez 2023 Mozambique	Before-after	cIPTp	+++++	1.80 (1.12, 2.91)
Gutman 2020 Burkina Faso	Cluster-RCT	cIPTp	<u>↓</u>	1.79 (1.21, 2.67)
Cosmic 2018 The Gambia	Cluster-RCT	ANC prom/cIST		1.75 (1.19, 2.56)
Gonzalez 2023 DRC	Before-after	cIPTp	→ →	1.62 (1.11, 2.35)
Gonzalez 2023 Madagascar	Before-after	cIPTp	<u></u>	1.55 (1.09, 2.20)
Gonzalez 2023 Nigeria	Before-after	cIPTp	┼ ╋┼─	1.52 (1.10, 2.09)
		I		
		.6	1 3	

Supplementary Figure 4: "Leave-one-out" forest plot for three or more doses or IPTp

Abbreviations: ANC prom, intervention by community health workers to promote ANC attendance and IPTp coverage. CHW, Community Health Worker. c-IPTp, intermittent preventive treatment delivered by community health workers (in addition to ANC). cIST, intermittent screening and treatment delivered by community health workers. Cluster-RCT, cluster randomized controlled trial. QE-parallel, quasi experimental trial with parallel arms. Before-after, a post-intervention survey is compared to a baseline survey. IPTp, intermittent preventive treatment in pregnancy. DRC, Democratic Republic of Congo.

[†] The pooled RR for IPTp3+ among these 10 studies was 1.73, 1.19-2.50 (ICC 0.06, see Supplementary table 5), which is indicated in the graph with the middle red dotted vertical line. In this graph, each study is removed one by one, so the effect of each study on the overall estimate can be assessed. E.g., when the Cosmic 2018 study in Benin was removed,³ the overall pooled estimate increased from 1.73 to 1.77. From the graph it can be deducted that the studies that have the largest effect on the overall estimate are the bottom three studies, by Gonzalez et al (2023) in DRC, Madagascar, and Nigeria.⁴ Removal of these studies reduced the effect, indicating that the effect in these countries must be higher than the overall pooled estimate. In Figure 2, it can be seen that these studies have an effect size of close to 3 or higher, e.g., resulted in large increases in IPTp3+, unlike all the other studies.

Publication and small study effect biases were assessed for IPTp3+ using Egger's test. Visual inspection of the funnel plot showed no clear indication of asymmetry (Figure 5).



Supplementary Figure 5: Funnel plot for three or more IPTp doses

Abbreviation: IPTp, intermittent preventive treatment in pregnancy (Egger's test p=0.35).

Supplementary Figure 6: Forest plot of difference-in-differences for two randomized trials comparing c-IPTp versus no c-IPTp for number of ANC visits

			Ν				Ν				
Outcome and	N Control		Intervention		N Control		Intervention			Effect	%
Study, Country	before	%	before	%	after	%	after	%		(95% CI)	Weight
ANC 1+											
Gutman 2020 Burkina Faso	186	89.4	188	90.3	180	94.4	180	97.8	+	0.02 (-0.11, 0.15)	100.00
Subgroup, DL (I ² = 0.0%, p =	.)								\diamond	0.02 (-0.11, 0.15)) 100.00
ANC 2+											
Rubenstein 2022 Malawi	188	97.4	182	98.4	344	94.6	343	95.3	+	-0.00 (-0.08, 0.08	3) 100.00
Subgroup, DL (I ² = 0.0%, p =	.)								\$	-0.00 (-0.08, 0.08	8) 100.00
ANC 3+											
Rubenstein 2022 Malawi	188	92.0	182	80.5	344	79.9	343	86.0	⊢∔ −	0.18 (0.01, 0.34)	100.00
Subgroup, DL ($I^2 = 0.0\%$, p =	.)								\diamond	0.18 (0.01, 0.34)	100.00
ANC 4+											
Gutman 2020 Burkina Faso	186	62.2	188	61.8	180	65.0	180	77.2	┼ ╺┼─	0.13 (-0.07, 0.32)	59.99
Rubenstein 2022 Malawi	188	63.4	182	46.9	344	48.1	343	56.8	 ; ↓	0.25 (0.01, 0.49)	40.01
Subgroup, DL ($I^2 = 0.0\%$, p =	0.422)								\diamond	0.18 (0.03, 0.33)	100.00
Heterogeneity between group	os: p = 0.08	3									
								-1	i 0	T 1	

Abbreviation: ANC, antenatal care. c-IPTp, Intermittent preventive treatment in pregnancy delivered in the community by community health workers.

	N sub- studies	No cluster adjustm	ent*	ICC estimate of 0.02 used*	ICC estimate of 0.02 used*		.06	ICC estimate of 0.0	9 used*	ICC estimate of 0.20 used*		
Number of ANC visits		Pooled RR, 95% CI and 95% prediction interval	<i>I</i> ² , %	Pooled RR, 95% CI and 95% prediction interval	<i>I</i> ² , %	Pooled RR, 95% CI and 95% prediction interval	I ² , %	Pooled RR, 95% CI and 95% prediction interval	<i>I</i> ² , %	Pooled RR, 95% CI and 95% prediction interval	<i>I</i> ² , %	
ANC1+	8	1.02, 1.01-1.03 0.99-1.05	94.3	1.02, 1.01-1.03 0.98-1.06	89.5	1.02, 1.00-1.04 0.97-1.08	82.1	1.02, 1.00-1.04 0.96-1.09	78.1	1.02, 0.99-1.05 0.96-1.09	62.0	
ANC2+	7	0·99, 0·89-1·11 0·66-1·51	97.8	0·99, 0·90-1·09 0·71-1·40	94.2	1.00, 0.92-1.08 0.76-1.31	88.2	$ \begin{array}{c} 1.00, 0.92 1.08 \\ 0.77 1.29 \end{array} $	84.6	$\frac{1 \cdot 01 \cdot 0.94 - 1.08}{0.83 - 1.24}$	69.1	
ANC3+	5	1.12, 1.07-1.17 0.99-1.26	25.1	1·12, 1·07-1·18 1·04-1·18	0.0	1·13, 1·06-1·20 1·02-1·25	0.0	1·13, 1·05-1·22 1·01-1·28	0.0	1·14, 1·04-1·26 0·97-1·34	0.0	
ANC4+	13	1.18, 1.02-1.37 0.65-2.15	95.5	1.18, 1.02-1.37 0.67-2.08	93.1	1.17, 1.01-1.36 0.67-2.04	90.3	1.18, 1.01-1.37 0.68-2.04	88.1	1.16, 0.99-1.35 0.69-1.94	81.1	
Early ANC visit‡												
Early ANC start	5	1.08, 0.99-1.19 0.84-1.39	35.4	1.05, 0.97-1.14 0.92-1.21	0.0	1.05, 0.96-1.16 0.90-1.23	0.0	1.05, 0.95-1.17 0.88-1.25	0.0	1.06, 0.92-1.21 0.85-1.32	0.0	

Supplementary Table 6: Meta-analyses for effect of interventions on number of ANC visits

Abbreviations: ANC: antenatal care. ICC; intracluster correlation coefficient. IPTp: intermittent preventive treatment in pregnancy. RR: risk ratio. Pooled risk ratios with a p-value < 0.05 have been printed in bold. Prediction interval

*Cluster adjustment was used for studies for which adjusted risk ratios or odds ratios were not available. The cluster adjustment was based on the ICC estimate. For studies which had an adjusted risk ratio or odds ratio available, this was always used in meta-analysis for each column. These include the following studies: Gutman 2020 Burkina Faso,¹ Mbonye 2007 Uganda,^{10,15} Msyamboza 2009 Uganda,⁸ Ndyomugyenyi 2009 Uganda,⁹ Okeibunor 2011 Nigeria,⁶ Orobaton 2016 Nigeria,¹¹ Rubenstein 2022 Malawi,² Wangalwa 2012 Kenya.⁷

[†]One sub-study not included because of 0 values.

‡ As defined by study: <14 weeks by Gies et al. (2009);⁵ in first trimester by Gonzales et al. (2023).⁴

short short <th< th=""><th></th><th>Ν</th><th colspan="3">No cluster adjustment*</th><th colspan="3">ICC estimate of 0.02 used*</th><th colspan="2">d* ICC estimate of 0.06 used*</th><th colspan="2">* ICC estimate of 0.09 used</th><th>used*</th><th colspan="2">* ICC estimate of 0.20 used*</th></th<>		Ν	No cluster adjustment*			ICC estimate of 0.02 used*			d* ICC estimate of 0.06 used*		* ICC estimate of 0.09 used		used*	* ICC estimate of 0.20 used*			
sind iss sind		Sub	3														
stade stade <tt< td=""><td></td><td>_</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tt<>		_															
its point RL, SN it point RL, SN point RL, SN it point RL, SN		stud															
Subgroup analyses No Poiled RR, 95% P, M P1 P0iled RR, 95% P, M P1 P0iled RR, 95% P1 P1 P1		ies															
C1	Subgroup analyses	105	Pooled RR. 95%	<i>I</i> ² . %	p†	Pooled RR. 95%	<i>I</i> ² .	p†	Pooled RR. 95%	<i>I</i> ² . %	p†	Pooled RR. 95%	<i>I</i> ² .	p†	Pooled RR. 95%	<i>I</i> ² . %	p†
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	819		CI	,	1 '	CI	%	1	CI	,	1 '	CI	%	1	CI	,	1 1
Intervention 9 15, 997-137 964 0.61 15, 906-137 927 0.91 15, 907-137 0.087 1-12, 0.92-137 8.48 0.93 ANC prom (1ST 2 1-12, 0.75-168 46.8 1-10, 0.85-169 168 1-20, 102-156 0.0 1.77, 103-157 0.0 1.77, 103-157 0.0 1.72, 103-157 0.0 1.72, 103-157 0.0 1.72, 103-157 0.0 1.72, 103-157 0.0 1.72, 103-157 0.0 1.73, 103-167 0.0 1.72, 103-157 0.0 1.73, 103-167 0.0 1.72, 103-157 0.0 1.72, 103-157 0.0 1.72, 103-157 0.0 1.72, 103-157 0.0 1.72, 103-157 0.0 1.72, 103-157 0.0 1.72, 113-142 0.0 1.72, 113-142 0.0 1.72, 113-142 0.0 1.72, 113-142 0.0 1.72, 103-157 0.0 1.72, 103-157 0.0 1.72, 113-142 0.0 1.72, 113-142 0.0 1.72, 113-142 0.0 1.72, 113-142 0.0 1.72, 113-142 0.0 1.72, 113-142 0.0 1.72, 113-142	ANC4+																
c-IPTp 9 1-15, 0.97-1-37 964 0.80 1-15, 0.96-1-37 92.7 0.90 1-15, 0.96-1-38 91.0 0.87 1-14, 0.94-1-37 84.8 0.93 ANC prom. 1 1-16, 1-36-1-90 - 1-63, 1-10, 2-42 - 1-61, 0.85-3-04 - 1-74, 0.80-3-78 - 1-71, 0.93-55 0 - - - - - 1-72, 1-03-1-57 0.0 - - - - - 1-25, 1-08-1-43 - 1-25, 1-08-1-43 - 1-25, 1-08-1-43 - 1-25, 1-08-1-43 - 1-25, 1-08-1-37 9 0.63 1-14, 0.95-1-37 9 0.61 1-15, 0.96-1-38 9 1-26, 1-12-1-42 0.0 - 1-26, 1-13-1-42 0.0 - 1-26, 1-12-1-42 0.0 - 1-26, 1-13-1-42 0.0 - 1-26, 1-12-1-42 0.0 - 1-26, 1-12-1-42 0.0 - 1-26, 1-12-1-42 0.0 - 1-26, 1-12-1-42 0.0 - 1-26, 1-12-1-42 0.0 - 1-26, 1-12-1-42 0.0 <td>Intervention</td> <td></td>	Intervention																
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	c-IPTp	9	1.15, 0.97-1.37	96.4	0.80	1.15, 0.96-1.37	94.9	0.84	1.14, 0.95-1.37	92.7	0.90	1.15, 0.96-1.38	91·0	0.87	1.14, 0.94-1.37	84.8	0.93
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	ANC prom/cIST	2	1.12, 0.75-1.68	46.8		1.20, 0.85-1.69	16.8		1.26, 1.02-1.56	0.0		1.27, 1.03-1.57	0.0		1.27, 1.03-1.57	0.0	
CHW home visits 1 125, 198-143 - 125, 198-143 100 125, 198-143 100 125, 198-143 100 125, 198-143 100 125, 198-143 115, 198-143 115, 198-143 115, 198-143 116, 198-143 116, 198-143 111, 107-146 111, 107	ANC prom	1	1.61, 1.36-1.90	-		1.63, 1.10-2.42	-		1.61, 0.85-3.04	-		1.74, 0.80-3.78	-		$1.71 \cdot 0.53 - 5.46$	-	
c-lPTp 9 1-15, 0-97-1-37 96-4 1-15, 0-96-1-37 92-7 0-1 1-15, 0-96-1-38 91-0 0-56 1-14, 0-94-1-37 84-8 0-61 Other than c-lPTp 4 1-32, 1-10-1-58 63-7 1-128, 1-14-1-43 0-0 1-26, 1-13-1-42 0-0 1-12, 0-21-1-42 0-0 1-26, 1-12-1-42 0-0 First dose in ANC 4 1-11, 0-76-1-16 98-3 1-11, 0-74-1-67 97.7 1-10, 0-72-1-69 96-8 1-12, 0-73-1-72 96-0 1-12, 0-72-1-74 93-4 Tisrt dose in ANC 7 1-11, 0-74-1-67 97.7 1-10, 0-72-1-69 96-8 1-12, 0-73-1-72 96-0 1-12, 0-72-1-74 93-4 Vis & c-lPTp 5 1-17, 1-10-1-33 82-4 0-84 1-15, 1-00-1-33 74-0 0-85 1-12, 0-73-1-72 96-0 1-12, 0-72-1-74 93-4 No & c-lPTp 4 1-32, 1-10-1-58 63-7 1-12, 1-14-1-43 0-0 1-12, 1-13-1-42 0-0 1-12, 0-73-1-74 93-4 No & c-lPTp 4 1-13, 1-01-1-34	CHW home visits	1	1.25, 1.08-1.43	-		1.25, 1.08-1.43	-		1.25, 1.08-1.43	-		1.25, 1.08-1.43	-		1.25, 1.08-1.43	-	
c-IPTp 9 115, 0.97-1.37 96-4 0:4 115, 0.96-1.37 92.7 0:61 115, 0.96-1.38 91.0 0.55 1-14, 0.94-1.37 84.8 0:61 First dose in ANC 9 1.23, 1.10-1.58 63:7 1.28, 1.14-1.43 0.0 1.26, 1.12-1.42 0.0 1.23, 1.24-1.42 0.0 1.26, 1.12-1.42 0.0 1.26, 1.12-1.42 0.0 1.26, 1.12-1.42 0.0 1.26, 1.12-1.42 0.0 1.26, 1.12-1.42 0.0 1.26, 1.12-1.42 0.0 1.26, 1.12-1.42 0.0 1.26, 1.12-1.42 0.0 1.26, 1.12-1.42 0.0 1.26, 1.12-1.42 0.0 1.26, 1.12-1.42 0.0 1.20, 0.72-1.74 93.4 0.61 1.10, 0.72-1.69 96.8 1.12, 0.73-1.72 96.0 1.11, 0.96-1.28 44.7 0.87 No & c-IPTp 4 1.10, 0.76-1.61 98.3 1.11, 0.74-1.67 97.7 1.10, 0.72-1.69 96.8 1.12, 0.73-1.72 96.0 0 1.26, 1.12-1.42 0.0 1.26, 1.12-0.72-1.74 93.4 0.61 1.12, 0.73-1.72 96.0 0 1.12, 0.72-1.74 93.4 0.61 1.12, 0.73-1.72 96.0 0 1.22, 0.72-1.74	c-IPTp vs no c-IPTp																
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	c-IPTp	9	1.15, 0.97-1.37	96.4	0.64	1.15, 0.96-1.37	94.9	0.63	1.14, 0.95-1.37	92.7	0.61	1.15, 0.96-1.38	91.0	0.56	1.14, 0.94-1.37	84.8	0.61
First dose in ANC 1 <th1< th=""> 1 1</th1<>	Other than c-IPTp	4	1.32, 1.10-1.58	63.7		1.28, 1.14-1.43	0.0		1.26, 1.13-1.42	0.0		1.27, 1.13-1.42	0.0		1.26, 1.12-1.42	0.0	
Yes 9 123, 107-1:36 7.7 0.59 121, 107-1:36 7.7 0.59 119, 106-1:34 64:1 0.59 117, 104-1:31 48:7 0.67 No 4 1:11, 0.76-1:61 98:3 0 1:11, 0.74-1:67 97.7 1:10, 0.072-1:69 68:8 1:12, 0.73-1:72 96:0 0 1:12, 0.72-1:74 93:4 Yes & c-IPTp 5 1:17, 102-1:35 86:8 0.85 1:17, 101-1:34 82:4 0.84 1:15, 100-1:33 74:0 0.83 1:12, 0.73-1:72 96:0 1:12, 0.72-1:74 93:4 No & c-IPTp 4 1:32, 1:10-1:58 63:7 1:12, 71:14-1:43 0:0 1:10, 0.71-1:41 0:0 1:10, 0.72-1:69 96:8 1:12, 0.73-1:72 96:0 1:12, 0.72-1:44 0:0 1:10, 0.72-1:69 96:8 1:12, 0.73-1:72 96:0 1:12, 0.72-1:44 0:0 1:10, 0.72-1:69 96:8 1:12, 0.73-1:72 96:0 1:12, 0.72-1:44 0:0 1:0 1:0, 0.72-1:69 96:8 1:12, 0.73-1:72 96:0 1:12, 0.72-1:44 0:0 1:0 0:0 1:0, 0.72-1:72 96:0 1:12, 0.72-1:44 0:0 1:0 <td>First dose in ANC</td> <td></td> <td>40 -</td> <td></td>	First dose in ANC															40 -	
No 4 1-11, 0-76-1-61 98:3 1-11, 0-74-1-67 97 1-10, 0-72-1-69 96-8 1-12, 0-73-1-72 96-0 1-12, 0-72-1-74 93-4 Yes & c-IPTp 5 1-17, 1-02-135 86-8 0-85 1-17, 1-01-134 82-4 0-84 1-15, 1-00-1-33 74-0 0-83 1-15, 0-99-1-34 69-3 0-81 1-11, 0-96-1-28 44-7 0-87 No & c-IPTp 4 1-10, 0-76-1-61 98-3 1-11, 0-74-1-67 97 1-10, 0-72-1-69 96-8 1-12, 0-73-1-72 96-0 1-12, 0-72-1-74 93-4 No & c-IPTp 4 1-10, 0-1-58 63-7 1-12, 1-74-1-74 97 1-10, 0-72-1-69 96-8 1-12, 0-73-1-72 96-0 1-12, 0-72-1-74 93-4 Vis & c-IPTp 4 1-11, 0-76-161 98-3 1-17, 0-71-134 82-4 0-76 1-15, 1-00-1-33 74-0 0-74 1-15, 0-91-33 74-0 0-71 1-12, 0-73-1-72 96-0 1-112, 0-72-1-74 93-4 Vis & c-IPTp 4 1-110, 0-74-1-67 97-7 <	Yes	9	1.23, 1.08-1.39	86.7	0.59	1.21, 1.07-1.36	77.5	0.59	1.19, 1.06-1.34	68.2	0.58	1.19, 1.06-1.34	64.1	0.59	1.17, 1.04-1.31	48.7	0.67
Inst dose in ANC Intr. 1:02-1:35 86.8 0:85 1:17, 1:02-1:35 86.8 0:85 1:17, 1:02-1:35 86.8 0:85 1:17, 1:02-1:42 0:0 1:15, 1:09-1:33 74:0 0:83 1:15, 0:99-1:34 69:3 0:81 1:11, 0:96-1:28 44:7 0:87 No & c-IPTp 4 1:22, 1:10-1:36 63:7 1:28, 1:14-1:43 0:0 1:26, 1:13-1:42 0:0 1:27, 1:13-1:42 0:0 1:22, 1:14-1:42 0:0 1:22, 0:73-1:72 96:0 1:12, 0:72-1:74 93:4 Yes & c-IPTp 5 1:17, 1:02-1:35 86:8 0:75 1:17, 1:01-1:34 82:4 0:76 1:15, 1:00-1:33 74:0 0:74 1:15, 0:99-1:34 69:3 0:78 1:11, 0:96-1:28 44:7 0:83 No & c-IPTp 4 1:10, 0:76-1:61 98:3 1:11, 0:74-1:67 97.7 1:10, 0:72-1:69 96:8 1:12, 0:73-1:72 96:0 1:12, 0:72-1:74 93:4 ANC4+ baseline	No	4	1.11, 0.76-1.61	98.3		1.11,0.74-1.67	97.7		1.10, 0.72-1.69	96.8		1.12, 0.73-1.72	96.0		1.12, 0.72-1.74	93.4	
Yes & c-IP1p 5 I-17, 142-135 86×8 0.*8 I-11, 0.741-67 97.7 I-11, 0.972-154 94.4 0.*8 I-11, 0.721-154 93.4 No & c-IPTp 4 I-13, 0.761-161 98.3 I-11, 0.741-67 97.7 I-10, 0.721-169 96.8 I-11, 0.731-12 96.0 I-126, 1-121-142 0.0 No & c-IPTp 4 I-13, 0.761-161 98.3 I-11, 0.741-67 97.7 I-10, 0.721-169 96.8 I-12, 0.731-172 96.0 I-126, 1-121-142 0.0 Yes & c-IPTp 5 I-17, 1-10-1-58 86.8 0.75 I-17, 1-10-1-34 82.4 0.76 I-15, 1-00-1-33 74.0 0.74 I-15, 0.99-1-34 69.3 0.81 I-11, 0.96-1-28 44.7 0.83 No & c-IPTp 4 I-11, 0.76-161 98.3 I-11, 0.74-167 97.7 I-10, 0.72-169 96.8 I-12, 0.73-172 96.0 I-11, 0.96-128 44.7 0.83 ANC4+ baseline I I-13, 0.74-167 97.7 I-10, 0.72-169 96.8 I-12, 0.73-172 96.0 I-11, 0.96-123 54.9 0.17 S50% 5 1-	First dose in ANC	-		06.0	0.05		00.4	0.04		54.0	0.02	1.15.0.00.1.04	(0.0	0.01	1 11 0 0 (1 0 0	44.5	0.07
No & c-IPTp 4 1+11, 0+6-1-61 98'3 1+11, 0+6-1-61 97'4 97'4 1+10, 0+2-1-69 96-8 1+12, 0+2-1-72 96-0 1+12, 0+2-1+74 93-4 No & c-IPTp 4 132, 1+10-1-58 63.7 1-28, 1+14-143 0.0 1-26, 1+13-1+42 0.0 1-27, 1+13-1+42 0.0 1-26, 1+12-1+24 0.0 1-26, 1+2-1+42 0.0 1-26, 1+2-1+42 0.0 1-26, 1+2-1+42 0.0 1-26, 1+2-1+42 0.0 1-26, 1+2-1+42 0.0 1-26, 1+2-1+42 0.0 1-26, 1+2-1+42 0.0 1-26, 1+2-1+42 0.0 1-26, 1+2-1+42 0.0 1-26, 1+2-1+42 0.0 1-26, 1+2-1+42 0.0 1-26, 1+2-1+42 0.0 1-26, 1+2-1+42 0.0 1-26, 1+2-1+42 0.0 1-26, 1+2-1+42 0.0 1-26, 1+2-1+42 0.0 1-26, 1+2-1+44 0.0 1-12, 0+7-2+14 0.0 1-12, 0+7-2+14 0.0 1-12, 0+7-2+14 0.0 1-12, 0+7-2+14 0.1 0.0 1-26, 1+2-144 0.0 1-26, 1+2-144 0.0 1-12, 0+7-2+14 0.0 1-12, 0+7-2+14 0.0 1-12, 0+7-2+14 0.0 1-12, 0+7-2+14 0.0 1-12, 0+7-2+14 0.0 <th< td=""><td>Yes & c-IPTp</td><td>5</td><td>1.17, 1.02-1.35</td><td>86.8</td><td>0.82</td><td>1·17, 1·01-1·34</td><td>82.4</td><td>0.84</td><td>1.15, 1.00-1.33</td><td>74.0</td><td>0.83</td><td>1.15, 0.99-1.34</td><td>69.3</td><td>0.81</td><td>1.11, 0.96-1.28</td><td>44.7</td><td>0.8/</td></th<>	Yes & c-IPTp	5	1.17, 1.02-1.35	86.8	0.82	1·17, 1·01-1·34	82.4	0.84	1.15, 1.00-1.33	74.0	0.83	1.15, 0.99-1.34	69.3	0.81	1.11, 0.96-1.28	44.7	0.8/
No c-P1P 4 152, 110-158 637 128, 114-143 0-0 122, 113-142 0-0 122, 113-142 0-0 122, 113-142 0-0 122, 113-142 0-0 122, 113-142 0-0 122, 113-142 0-0 122, 113-142 0-0 122, 113-142 0-0 122, 113-142 0-0 122, 113-142 0-0 122, 113-142 0-0 122, 113-142 0-0 122, 113-142 0-0 122, 113-142 0-0 123, 113, 0-9 0-0 123, 0-9	No & c-IPTp	4	1.11,0.76-1.61	98.3		1.11,0.74-1.67	97.7		1.10, 0.72-1.69	96.8		1.12, 0.73-1.72	96.0		1.12, 0.72-1.74	93.4	
Pirst dose in ANC Int, 1u2-1:35 86:8 0.75 1:17, 1:01-1:34 82:4 0.76 1:15, 1:00-1:33 74:0 0.74 1:15, 0:99-1:34 69:3 0.75 1:11, 0:74-1:67 97:7 1:10, 0:72-1:69 96:8 1:12, 0:73-1:72 96:0 1:11, 0:96-1:28 44:7 0:83 ANC4+ baseline I <th< td=""><td>No c-IP Ip</td><td>4</td><td>1.32, 1.10-1.58</td><td>63.7</td><td></td><td>1.28, 1.14-1.43</td><td>0.0</td><td></td><td>1.26, 1.13-1.42</td><td>0.0</td><td></td><td>1.27, 1.13-1.42</td><td>0.0</td><td></td><td>1.26, 1.12-1.42</td><td>0.0</td><td></td></th<>	No c-IP Ip	4	1.32, 1.10-1.58	63.7		1.28, 1.14-1.43	0.0		1.26, 1.13-1.42	0.0		1.27, 1.13-1.42	0.0		1.26, 1.12-1.42	0.0	
Yes & C-IP Ip 5 1-17, 1-02-1-35 86-8 0.75 1-17, 1-01-1-34 82-4 0.76 1-15, 1-00-1-33 74-0 0.74 1-15, 0-99-1-34 69-3 0.78 1-11, 0-96-1-28 44-7 0-83 No & c-IPTp 4 1-11, 0-76-1-61 98-3 1-11, 0-74-1-67 97.7 1-10, 0-72-1-69 96-8 1-12, 0-73-1-72 96-0 1-12, 0-72-1-74 93-4 ANC4+ baseline - <td>First dose in ANC</td> <td>-</td> <td>1 15 1 00 1 05</td> <td>06.0</td> <td>0.75</td> <td>1 15 1 01 1 24</td> <td>02.4</td> <td>0.76</td> <td>1 15 1 00 1 22</td> <td>74.0</td> <td>0.74</td> <td>1 15 0 00 1 24</td> <td>(0.2</td> <td>0.70</td> <td>1 11 0 06 1 20</td> <td>44.7</td> <td>0.02</td>	First dose in ANC	-	1 15 1 00 1 05	06.0	0.75	1 15 1 01 1 24	02.4	0.76	1 15 1 00 1 22	74.0	0.74	1 15 0 00 1 24	(0.2	0.70	1 11 0 06 1 20	44.7	0.02
No & c-IP Ip 4 1-11, 0-76-1-61 98:3 1-11, 0-74-1-67 97.7 1-10, 0-72-1-69 96.8 1-12, 0-73-1-72 96.0 1-12, 0-72-1-74 93.4 ANC4+ baseline 5 1-28, 0-99-1-66 95:3 0-28 1-29, 1-02-1-62 89.9 0.26 1-28, 1-04-1-58 82.6 0-27 1-30, 1-08-1-58 74.1 0-21 1-29, 1-09-1-53 54.9 0.17 $\leq 50\%$ 5 1-05, 0.86-1-28 96.2 1-05, 0.86-1-29 95.1 1-05, 0.85-1-29 93.2 1-05, 0.85-1-30 91.8 1-03, 0.83-1-28 86.0 IPTp2+ baseline	Yes & c-IPTp	5	1.17, 1.02-1.35	86.8	0.75	1.17, 1.01-1.34	82.4	0.76	1.15, 1.00-1.33	74.0	0.74	1.15, 0.99-1.34	69.3	0.78	1.11, 0.96-1.28	44.7	0.83
ANC4+ baselineImage: constraint of the state	No & c-IP Ip	4	1.11, 0.76-1.61	98.3		1.11,0.74-1.67	9/./		1.10, 0.72-1.69	96.8		1.12, 0.73-1.72	96.0		1.12, 0.72-1.74	93.4	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	ANC4+ baseline	0	1 29 0 00 1 ((05.2	0.29	1 20 1 02 1 (2	80.0	0.20	1 20 1 04 1 50	02 (0.27	1 20 1 00 1 50	74.1	0.21	1 20 1 00 1 52	54.0	0.17
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	<50%	8	1.28, 0.99-1.66	95.3	0.78	1.29, 1.02-1.62	89.9	0.26	1.28, 1.04-1.58	82.6	0.7	1.30, 1.08-1.38	/4.1	0.71	1.02,0.02,1.20	54.9	0.1/
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	<u>></u> 50%	5	1.05, 0.86-1.28	96.2		1.05, 0.86-1.29	95.1		1.05, 0.85-1.29	93.2		1.05, 0.85-1.30	91.8	1	1.03, 0.83-1.28	86.0	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	IP Ip2+ baseline	0	1 24 1 02 1 50	0(1	0.45	124 1 02 1 40	04.7	0.46	1 22 1 01 1 49	02 (0.40	1 22 1 01 1 49	01.2	0.57	1 10 0 00 1 44	96.2	0.70
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	<00%	9	1.07.0.80.1.42	90.1	0.43	124, 1.02-1.49	94.7	0.40	1.07.0.92.1.29	92.0	0.49	1 11 0 90 1 29	91.2	0.37	1.19, 0.98-1.44	80.2	0.70
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	≥00% IDTr2 hasalina	4	1.07, 0.80-1.43	94.0		1.07, 0.82-1.39	88.3		1.07, 0.83-1.38	/9.4		1.11, 0.89-1.38	62.9	-	1.15, 0.94-1.39	20.3	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	IP 1 p 3+ baseline	7	1.19 0.09 1.42	06.1	0.02	1.16 0.08 1.20	04.5	0.00	1.14 0.05 1.26	02.4	0.71	1.12 0.04 1.26	01.0	0.60	1.11 0.02 1.22	86.0	0.50
24 117, 109-130 00 122, 107-139 00 122, 107-143 00 124, 103-140 00 Design QE-parallel 2 1:27, 0:44-3:66 98:8 0:84 1:27, 0:44-3:69 98:3 0:83 1:25, 0:43-3:69 97:2 0:81 1:30, 0:46-3:62 95:8 0:69 1:30, 0:47-3:60 91:8 0:61 Cluster-RCT 6 1:27, 1:14-1:42 56:9 1:24, 1:14-1:34 0:0 1:24, 1:13-1:36 0:0 1:25, 1:13-1:38 0:0 1:25, 1:12-1:39 0:0 Before-After‡ 5 1:10, 0:89-1:35 96:6 1:10, 0:89-1:35 95:7 1:09, 0:88-1:34 94:1 1:08, 0:87-1:33 92:8 1:06, 0:86-1:32 88:1 Quality assessment Moderate 8 1:19, 0:97-1:46 97:1 0:91 1:18, 0:96-1:44 95:5 0:99 1:16, 0:94-1:42 93:6 0:86 1:16, 0:94-1:43 92:0 0:78 1:14, 0:92-1:41 86:6 0:73	<u>\40%</u>	/	1.10 1.00 1.20	90.1	0.92	1.20 1.08 1.24	94.5	0.90	1.22 1.07 1.20	92.4	0.11	1.24 1.07 1.43	91.0	0.00	1.24 1.05 1.46	0.0	0.39
Design	24070	4	1.19, 1.09-1.30	0.0		1.20, 1.00-1.34	0.0		1.22, 1.07-1.39	0.0		1.24, 1.07-1.43	0.0		1.24, 1.03-1.40	0.0	
Cluster-RCT 6 1·27, 1·14-1·42 56·9 1·24, 1·14-1·34 0·0 1·24, 1·13-1·36 0·0 1·25, 1·13-1·38 0·0 1·25, 1·13-1·38 0·0 1·25, 1·13-1·38 0·0 Before-After‡ 5 1·10, 0·89-1·35 96·6 1·10, 0·89-1·35 95·7 1·09, 0·88-1·34 94·1 1·08, 0·87-1·33 92·8 1·06, 0·86-1·32 88·1 Quality assessment	OE parallel	2	1.27 0.44 3.66	08.8	0.84	1.27 0.44 3.69	08.3	0.83	1.25 0.43 3.60	07.2	0.81	1.30 0.46 3.62	05.8	0.60	1.30 0.47 3.60	01.8	0.61
Before-After‡ 5 1·10, 0·89-1·35 96·6 1·10, 0·89-1·35 95·7 1·09, 0·88-1·34 94·1 1·10, 0·87-1·33 92·8 1·10, 0·86-1·32 88·1 Quality assessment Moderate 8 1·19, 0·97-1·46 97·1 0·91 1·18, 0·96-1·44 95·5 0·99 1·16, 0·94-1·42 93·6 0·86 1·16, 0·94-1·43 92·0 0·78 1·14, 0·92-1·41 86·6 0·73	Cluster-BCT	6	1.27, 0 44-3 00	56.0	0.04	1.74 1.14_1.34	0.0	0.05	1.23, 0 43-3 09	0.0	0.01	1.25 1.13_1.38	0.0	0.09	1.25 1.12-1.30	0.0	0.01
Quality assessment 8 1:19, 0:97-1:46 97:1 0:91 1:18, 0:96-1:44 95:5 0:99 1:16, 0:94-1:42 93:6 0:86 1:16, 0:94-1:43 92:0 0:78 1:14, 0:92-1:41 86:6 0:73	Refore_After*	5	1.10 0.89-1.35	96.6		1.10 0.89-1.35	95.7		1.09 0.88-1.34	94.1		1.08 0.87-1.33	92.8		1.06 0.86-1.32	88.1	
Moderate 8 1:19, 0:97-1:46 97:1 0:91 1:18, 0:96-1:44 95:5 0:99 1:16, 0:94-1:42 93:6 0:86 1:16, 0:94-1:43 92:0 0:78 1:14, 0:92-1:41 86:6 0:73	Quality assessment	5	1 10, 0 07-1 33	20.0		1 10, 0 07-1 33	951		1 09,0 00-1 54	241		1 00, 0 07-1 33	92 0		1 00,0 00-1 52	00 1	
$\frac{1}{100000000} = \frac{1}{10000000000000000000000000000000000$	Moderate	8	1.19 0.07-1.46	97.1	0.01	1.18 0.96-1.44	95.5	0.00	1.16 0.94-1.42	93.6	0.86	1.16 0.94-1.43	92.0	0.78	1.14 0.92-1.41	86.6	0.73
Good 5 1:21 1:12-1:30 0:0 1:22 1:12-1:33 0:0 1:23 1:12-1:36 0:0 1:24 1:13-1:37 0:0 1:24 1:12-1:38 0:0	Good	5	1.21, 1.12-1.30	0.0	0 71	1.22 1.12-1.33	0.0	0))	1.23, 1.12-1.36	0.0	0.00	1.24, 1.13-1.37	0.0	0 /0	1.24, 1.12-1.38	0.0	015

Supplementary Table 7: Subgroup analyses, including sensitivity analyses, for effects of interventions on four or more ANC visits

Abbreviations: ANC: antenatal care. Before-after: study design where an intervention is implemented and compared with a baseline survey. cIST: intermittent screening and testing for malaria by community health workers. c-IPTp: intermittent preventive treatment provided by community health workers (as opposed to ANC only). CHW: community health workers. ICC; intracluster correlation coefficient. IPTp: intermittent

preventive treatment in pregnancy. QE-parallel: quasi-experimental study with parallel design (control and intervention group measured at the same time). RCT: randomized controlled trial. ANC prom: intervention by CHWs to promote ANC attendance and IPTp coverage.

*No cluster adjustment for studies for which adjusted risk ratios or odds ratios were not available. For studies that had an adjusted risk ratio or odds ratio available, this was always used in meta-analysis.

[†]P-value subgroup analysis, obtained by meta-regression.

‡Comparing Before-After studies and other designs p>0.05, e.g., for first column p-value Cluster RCT vs. Before-After: p=0.67

Influence of individual sub-studies on pooled estimate for ANC4+ and funnel plot

A "leave-one-out" forest plot showing the effect of when each study is removed on the pooled ANC4+ coverage is presented in Supplementary Figure 7 with one study showing a more extreme effect.⁹ Publication and small study effect biases were assessed for ANC4+ using Egger's test and visual inspection of the funnel plot. There was no clear indication of asymmetry (Egger's test p=0.51) (Supplementary Figure 8).

Study, Country omitted	Design	Intervention		Risk Ratio† (95% CI)
Mbonye 2007* Uganda	QE-parallel	cIPTp		- 1.22 (1.04, 1.42)
Gonzalez 2023 Mozambique	Before-after	clPTp	╎╶┼╸┤	 1.22 (1.07, 1.40)
Cosmic 2018 The Gambia	Cluster-RCT	ANC prom/cIST		1.18 (1.01, 1.37)
Gonzalez 2023 Nigeria	Before-after	clPTp		- 1.20 (1.00, 1.44)
Gonzalez 2023 DRC	Before-after	clPTp	+++	1.17 (0.99, 1.39)
Gutman 2020 Burkina Faso	Cluster-RCT	clPTp		1.17 (0.99, 1.37)
Rubenstein 2022 Malawi	Cluster-RCT	clPTp	<u> </u>	1.17 (0.99, 1.37)
Kayentao 2023 Mali	Cluster-RCT	CHW home visits		1.16 (0.99, 1.37)
Cosmic 2018 Burkina Faso	Cluster-RCT	ANC prom/cIST		1.16 (0.99, 1.36)
Gonzalez 2023 Madagascar	Before-after	clPTp		1.16 (0.98, 1.36)
Wangalwa 2012 Kenya	Before-after	clPTp		1.14 (0.98, 1.33)
Gies 2009 Burkina Faso	Cluster-RCT	ANC prom	<u> </u>	1.15 (0.99, 1.35)
Ndyomugyenyi 2009 Uganda	QE-parallel	cIPTp	+++-	1.11 (0.96, 1.27)
		۱ .6	1	1.5

Supplementary Figure 7: "Leave-one-out" forest plot for four or more ANC visits

Abbreviations: ANC, antenatal care. ANC prom, intervention by community health workers to promote ANC attendance and IPTp coverage. c-IPTp, intermittent preventive treatment delivered by community health workers (in addition to ANC). cIST, intermittent screening and treatment delivered by community health workers. Cluster-RCT, cluster randomized controlled trial. QE-parallel, quasi experimental trial with parallel arms. Before-after, a post-intervention survey is compared to a baseline survey. IPTp, intermittent preventive treatment in pregnancy. DRC, Democratic Republic of Congo.

*Denominator for IPTp2+ was women who had received 1 dose of SP

[†] The pooled RR for ANC4+ among these 13 studies was $1 \cdot 17$, $1 \cdot 01 - 1 \cdot 36$ (ICC $0 \cdot 06$, see Supplementary table 6), which is indicated in the graph with the middle red dotted vertical line. In this graph, each study is removed one by one, so the effect of each study on the overall estimate can be assessed. E.g., when the Mbonye 2007 study in Uganda was removed, the overall pooled estimate increased from $1 \cdot 17$ to $1 \cdot 22$. From the graph it can be deducted that the studies that have the largest effect on the overall estimate are by Mbonye et al (2007) in Uganda,^{10,15} Gonzalez et al (2023) in Mozambique,⁴ and Nydomugyenyi et al (2009) in Uganda.⁹ Removal of the first two studies increased the effect, indicating that the effect in these countries must be lower than the overall pooled estimate, whereas removal of the bottom study results in a decrease, indicating the effect must be higher than the pooled estimate in that study. In Figure 3 it can be seen that the first two studies show a decrease in ANC visits in the intervention arm, whereas the bottom study by Ndyomugyenyi⁹ showed an increase of ANC uptake in the intervention arm.



Abbreviation: ANC, antenatal care (Egger's test p=0.51)

Supplementary Table 8: Checklist for quality reporting: Mixed Methods Studies

Author/Year	N	Justification for using mixed methods	Sampling strategy reported		Methods for qualitative component reported	An str: rep	alysis ategy orted	Multivariat e Analysis used	Minimization of bias reported	Integration of Quant/Qual components	Total (9)
			Qualitative	Quantitative		Qual	Quant				
Mbonye 2007 ¹⁵	1429	No	No	Yes	Yes	No	Yes	No	No	Yes	4/9
Okedo-Alex 2022 ¹⁶	817	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	No	7/9

Description of categories:

Justification – authors offer justification for the use of mixed methods in the study.

Sampling – authors report on the sampling techniques for both the qualitative and quantitative participant selection.

Methods - authors report the methodological techniques in data collection for the qualitative components.

Analysis – authors report the analysis strategy used for both the qualitative and quantitative components.

Bias – authors report the steps taken to minimize bias either through study design or in the analysis.

Integration - authors integrate the qualitative and quantitative components in the analysis and findings.

Supplementary Table 9: Checklist for quality reporting: Qualitative studies

Author/Year	N	Sampling strategy is justified	Data collection is clearly explained	Saturation is mentioned	Analysis is clearly explained	Reflexivity is documented	Reliability & Validity is discussed	Use of findings is discussed	Total (7)
Burke 2021 ¹⁷	139	Yes	Yes	No	Yes	No	Yes	Yes	5/7
Alonso 2022 ¹⁸	3235	Yes	Yes	No	Yes	Yes	Yes	Yes	6/7

Description of categories:

Sampling strategy - the author mentions who was sampled, how they were sampled and whether or not it is justified.

Data Collection - the methods are described sufficiently in the article, and it mentions if focus group facilitators/interviewers were trained.

Saturation – the author discusses saturation of data.

Analysis - the methods for analysis described and justified.

Reflexivity - the author discusses the effect of the researcher/trial on the data/observations.

Reliability & Validity – triangulation with other data or methods used to confirm/check the results, or validation of the transcripts with the participants to ensure accuracy of data. Findings – the findings discussed for their implications on further research, policy or programming.

Main themes	Secondary themes	Primary themes	References
Malaria knowledge and health care seeking	Lack of awareness of malaria prevention in pregnancy, and	Misconception about malaria transmission	15,16
practices	the intervention	Lack of awareness of the negative effects of malaria in pregnancy	15
	lack of women's knowledge on the consequences of malaria in pregnancy	Lack of knowledge on malaria prevention in pregnancy	9,15
	lack of the knowledge of the importance of ANC care	Morbidity and care seeking practices	9,15,17
		Fear of being pricked	15
		Feeling well and not needing medication	9,15
		Negligence	15
Fear of SP side effects and adverse events		Negative perception of SP, rumours about SP	15,16,18,19
		Perceived and experienced side effects	15,16,18,19
Gender inequities in traditional gender roles	Influence on women' health seeking behaviour	Household chores; looking after children; needing relative support; needing husbands' permission; lack of family support;	15,17,19
	Role of CHWs' gender in effectiveness	CHWs' discomfort with certain tasks; male CHWs needing husband's permission to interact with PW; female CHWs needing husband's permission to go to work.	17-19
Socio-cultural and religious influence	Role of CHWs' gender in effectiveness.	Pregnancy disclosure norms;	9,17-19
Organization of health services delivery, and		High cost of services	15,18,19
inadequate CHWs'		Long distance to health facility	9,18,19
working conditions		Poor quality of services	9
		Shortage of drugs	9,15
	Unsuitable CHWs working conditions	Lack of transportation means for CHWs	17-19
		CHWs' low remuneration	18,19
Lack of trust in CHWs	Scepticism in CHWs competence; CHWs' lack of specialized training; CHWs' need for support	Perceived lack of CHWs' competence; mistrust in CHWS; CHWs low literacy level;	17-19
	Need for clear community's understanding of CHWs' role	CHWs not being accepted by the community.	17
		not meeting women's needs;	17

Supplementary Table 10: Themes related to barriers to community IPTp promotion or delivery

 understanding of CHWs' role
 not meeting women's needs;
 17

 Abbreviations: ANC, antenatal clinic. CHWs, community health workers. SP, sulfadoxine-pyrimethamine. PW, pregnant women.
 Data from both Okedo-Alex 2020²⁰ and Okedo-Alex 2022 were combined.¹⁶ Data from both Enguita-Fernandez 2020¹⁹ and Alonso 2022 were combined.¹⁸

Main themes	Secondary themes	Primary themes	References
CHW traits and trust	Women's trust in CHWs; kindship structures	CHWs known, chosen by the community	9,15,16
	CHWs ability to convince husbands through explanation of the strategy;	Ability of CHWs to convince husbands	15
	encouragement of women	CHWs reminding women of the next dose	9
		CHWs being kind, approachable, and understanding	15,18,19
		CHWs' gender equity (existence of male and female)	17
	commitment to their work; task simplicity	CHWs' feeling capable	9,17
		CHWs' role in improving health of the community	9,17
CHW capabilities and their role in linking the	Linking CHWs to health units; integration of c-IPTp in health	Pre-existing CHWs	9,15,18,19
community with health facilities	systems; bridging community to health systems.	Training and regular supervision of CHWs	15,17-19
includes	iteriti systemsi	Linking community to health facilities	15,17-19
		community-clinic partnership	17
CHW accessibility	Easy accessibility of CHWs and their ability to conduct home visits	Home visits; CHWs being accessible	9,15
	ability to conduct nome visits	No walking long distance	9
Community sensitization and engagement	Community engagement Sustainability of the approach	Community sensitization	15,17-19
		Mass media campaigns	15,17-19
		Use of local council meetings, drama groups, Seminars targeting men Women encouraging other women	15
		Community involvement	9,16-19
		Community support	17
		Local authorities' involvement	18,19
Women's knowledge on malaria and positive	Knowledge of malaria; awareness of the benefits of malaria prevention in	Previous experience with malaria and symptoms	15
view of SP and c-IPTp	pregnancy	Knowledges of malaria consequences	9,15,16
and perceived benefits		Previous use of IPTp-SP; improved health with first dose	15,18,19
		Medical pluralism	18,19
	Benefits to the community	Desire to produce a healthy baby	15
	Positive view of SP	Positive view of SP; perceived quality of SP	9,15-19
	Positive perception of c-IPTp	Positive view of c-IPTp	9,16
Support from husband and relatives		Husband's support; support from relatives	21

Supp	lementary	Table 11:	Themes	related to	facilitators	of c	ommunity	IPT ₁	p deliver	٢v
	/						/			

Abbreviations: CHWs, community health workers. IPTp-SP, intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine. cIPTp, community delivery of IPTp Data from both Okedo-Alex 2020²⁰ and Okedo-Alex 2022 were combined.¹⁶ Data from both Enguita-Fernandez 2020¹⁹ and Alonso 2022 were

combined.18

Supplementary Table 12: Lists of records excluded and reasons for exclusion

References	Reasons for exclusion
Adjei DJD. Factors affecting the intermittent preventive therapy of malaria in pregnancy programme in the Ejisu-Juabeng municipality [Internet] [Thesis]. 2009. Available from: http://dspace.knust.edu.gh:8080/jspui/bitstream/123456789/67/1/INTRODUCTION.Addison%203%20orig.pdf	Not community intervention of IPTp meeting eligibility criteria
Afolabi BM, Okoh F, Fatunmbi S, Komakech W, Sallu O, Ewoigbokhan F, et al. Combined intervention of intermittent preventive therapy and long-lasting insecticide treated nets among pregnant women in Nigeria [Internet]. Vol. 3, Journal of Public health and Epidemiology. 2011. p. 608–16. Available from: http://www.heendef.org.ng/Document/Afolabi%20et%20al_published.pdf	Not community intervention of IPTp meeting eligibility criteria
Agyare CS. Evaluating the implementation of intermittent preventive treatment (IPTp) programme using sulphadoxine pyrimethamine for the control of malaria in pregnancy in the Kwabre District of Ghana [Internet] [Thesis]. 2008. Available from: http://dspace.knust.edu.gh:8080/jspui/bitstream/123456789/72/1/PART%20-%203.pdf	Not community intervention of IPTp meeting eligibility criteria
Anoke C, Orji B, Bryce E, Oliveras E, Enne J, Njoku E, et al. Comparative analysis of facility and community distribution of intermittent preventive treatment of malaria in pregnancy: Evidence from maternity record booklet in Ohaukwu, Ebonyi State Nigeria. In American Journal of Tropical Medicine and Hygiene; 2022. p. 121. Available from: https://www.astmh.org/getmedia/65cc0d8d-1208-4d9a-9f77-734d40de4c02/ASTMH-2022-Annual-Meeting-Abstract-Book.pdf	Conference abstract, insufficient details
Antimalarial drugs: costs, safety, and efficacy. Hauppauge, NY : Nova Science, c2009.; 2009.	Not community intervention of IPTp meeting eligibility criteria
Apat, D., Akhwale, W., Kidi, M., et al. Increasing access to malaria in pregnancy services through community health units and enhanced supportive supervision of community health volunteers [Internet]. Vol. 103, American Journal of Tropical Medicine and Hygiene. p. 123.	Conference abstract, insufficient details
Badolo, O., Tiendrebeogo, J., Sawadogo, Y., et al. Scale up of intermittent preventive treatment of malaria in pregnancy (IPTp) by community health workers following the results of a feasibility pilot in Po District, Burkina Faso [Internet]. Available from: http://app.core-apps.com/tristar_astmh21/abstract/b7438cf1-19e4-4f13-a4fc-452eea1120ec	Data captured in the review from other publications
Beyai P. The cost-effectiveness of intermittent preventive treatment for malaria in Gambian multigravidae including examination of indirect costs [Internet] [Thesis]. 2010. Available from: http://ethos.bl.uk/OrderDetails.do?did=6&uin=uk.bl.ethos.504541	Not community intervention of IPTp meeting eligibility criteria
Bigirwa P. Effectiveness of community health workers (CHWS) in the provision of basic preventive and curative maternal, newborn and child health (MNCH) interventions: a systematic review [Internet]. Vol. 7, Health Policy and Development. 2009. p. 162–72. Available from: http://www.bioline.org.br/pdf?hp09013	Review, not an original research study
Brieger, R. W, Burke, D., Tiendrebeogo, J., et al. Feasibility study on intermittent preventive treatment of malaria in pregnancy at the community level in Burkina Faso; Implementation research for testing new approaches to improving prevention of malaria in pregnancy [Internet]. 2020 Mar. Available from: https://endmalaria.org/sites/default/files/Burkina%20Faso%20C-IPTp%20Study%20Report%20FINAL.pdf	Data captured in the review from other publications
Brieger, W.R., Dodo, M., Burke, D., et al. Community based health workers can enhance coverage of intermittent preventive treatment of malaria in pregnancy and promote antenatal attendance [Internet]. Available from: www.abstractsonline.com/pp8/#!/4692/presentation/19636	Data captured in the review from other publications
Chinkhumba, J., Rubenstein, L. B, Chillima, E., et al. Impact of community delivery on coverage of intermittent preventive treatment for malaria in pregnancy in Malawi [Internet]. Available from: http://app.core-apps.com/tristar_astmh21/abstract/569e6a11-b01b-40c9-8383-d6d4d6bf5e0f	Conference abstract, insufficient details
Ciapponi A, Lewin S, Herrera CA, Opiyo N, Pantoja T, Paulsen E, et al. Delivery arrangements for health systems in low- income countries: an overview of systematic reviews [Internet]. Cochrane Database of Systematic Reviews. 2017. Available from: http://dx.doi.org/10.1002/14651858.CD011083.pub2	Did not report on the outcomes of interest (IPTp and ANC).
Denakpo B, Togbenou J, Dagnon JF, Amegnikou DE, Amoussou SI, Hounkpe B, et al. Assessment of behavior change communication (BCC) interventions in support of malaria control activities conducted in Benin by pmi's ARM3 project [Internet]. Vol. 97, American journal of tropical medicine and hygiene. Conference: 66th annual meeting of the american society of tropical medicine and hygiene, ASTMH 2017. United states. 2017. p. 335.	Conference abstract, insufficient details

Deogratias, N. C, Ketembwe, F., Ekandji, J., et al. The contribution of community delivery to the uptake of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine in three districts of the Democratic Republic of the Congo [Internet]. Available from: http://app.core-apps.com/tristar_astmh21/abstract/cd43c5c6-76eb-4828-a62d-be808994ea6d	Conference abstract, insufficient details
Diala C, Pennas T, Choi P, Rogers S. Barriers to uptake of malaria prevention and treatment during pregnancy in Cross River and Nasawara States, Nigeria [Internet]. 2012 Jan. Available from: http://www.c- changeprogram.org/sites/default/files/Barriers-to-Uptake-of-Malaria-Prevention-and-Treatment.pdf	Not community intervention of IPTp meeting eligibility criteria
Duong M, Swadogo Y, Guimas JL, Yonli C, Moyenga I, Grimaldi M, et al. Assessing information, education and behavior change intervention in a malaria control program implemented in Ouahigouya district, Burkina Faso [Internet]. Vol. 16, Tropical Medicine and International Health. p. 147–147.	Conference abstract, insufficient details
E.O. T, Lawson B, Browne E. The effectiveness and perception of the use of sulphadoxine-pyrimethamine in intermittent preventive treatment of malaria in pregnancy programme in Offinso District of Ashanti Region, Ghana [Internet]. Vol. 10, Malaria Journal. 2011. p. 385 PMID 22206597. Available from: http://www.malariajournal.com/content/pdf/1475-2875-10-385.pdf	Not community intervention of IPTp meeting eligibility criteria
Ghana M of H. Accelerating Access to Prevention and Treatment of Malaria through Scaling-Up of Home-Based Care and Indoor Residual Spraying Towards the Achievement of the National Strategic Goal. Ghana Global Fund Proposal Round 8 [Internet]. 2008 Jan. Available from: http://www.theglobalfund.org/grantdocuments/8GHNM_1678_0_full.pdf	Limited details, not sufficient data to include
Ghansah G. Factors promoting and preventing the utilization and uptake of IPT among pregnant women in the Mampong Municipality,Ghana [Internet] [Thesis]. 2016. Available from: http://hdl.handle.net/123456789/9122	Not community intervention of IPTp meeting eligibility criteria
Gonzalez R, Sacoor C, Arikpo I, Mbombo Ndombe D, Ramananjato R, Llach M, et al. Effect of community delivery of intermittent preventive treatment (IPTp) of malaria in pregnancy on coverage of IPTp in four sub-Saharan African Countries. In American Journal of Tropical Medicine and Hygiene; 2022. p. 552. Available from: https://www.astmh.org/getmedia/65cc0d8d-1208-4d9a-9f77-734d40de4c02/ASTMH-2022-Annual-Meeting-Abstract-Book.pdf	Data captured in the review from other publications
Goodman CA, Coleman P, Mills AJ. Cost-effectiveness of malaria control in sub-Saharan Africa [Internet]. Vol. 354, Lancet. 1999. p. 378-385 PMID 10437867. Available from: http://dx.doi.org/10.1016/S0140-6736(99)02141-8	Modeling cost analysis
Gueye AB, Gaye S, Ba F, Ndiop M, Diallo I, Cisse M, et al. Impact of the application of the new guidelines of malaria case management in Senegal [Internet]. Vol. 95, American Journal of Tropical Medicine and Hygiene. p. 510–510.	Conference abstract, insufficient details
Hartman AF, Polich E, Rumunu J, Mohammed J. Increasing malaria prevention in pregnant women in South Sudan [Internet]. Online program 141st APHA Annual Meeting. Available from: https://apha.confex.com/apha/141am/webprogramadapt/Paper289694.html	Conference abstract, insufficient details
Hartman AF, Rumunu J. Rapid increase in malaria services for pregnant women in South Sudan [Internet]. Vol. 89, American Journal of Tropical Medicine and Hygiene. p. 115–115.	Conference abstract, insufficient details
Houndjo, W. Improving intermittent preventive treatment for pregnant women (IPTp) coverage using community-based outreach strategy in 2 health zones in Benin [Internet]. Vol. 101, American Journal of Tropical Medicine and Hygiene. p. 313.	Conference abstract, insufficient details
ISRCTN37259296. Community-based scheduled screening and treatment of malaria in pregnancy for improved maternal and infant health [Internet]. 2013. Available from: http://isrctn.com/ISRCTN37259296	Data captured in the review from other publications
JHPIEGO, Maternal, Program CHI. Community directed intervention for malaria prevention in pregnant women [Internet]. 2011 Jan. Available from: http://www.mchip.net/sites/default/files/maternal%20USAID%20approved%20and%20final%20brief- %20community%20MIP.PDF	Data captured in the review from other publications
JHPIEGO. Community Intermittent Preventive Treatment for Malaria in Pregnancy Learning Resource Package [Internet]. 2018 Dec. Available from: http://resources.jhpiego.org/resources/C-IPTp-LRP	Limited details, not sufficient data to include
JHPIEGO. Preventing malaria in pregnancy through focused antenatal care: working with faith-based organization in Uganda [Internet]. 2007 Jan. Available from: http://pdf.usaid.gov/pdf_docs/PNADJ433.pdf	Limited details, not sufficient data to include
JHPIEGO. Rapid facility assessments of malaria in pregnancies practices [Internet]. 2020 Dec. Available from: http://resources.jhpiego.org/resources/rapid-facility-assessments-malaria-pregnancy-practices	Limited details, not sufficient data to include

Kayentao, K., Diawara, I. S, Gutman, J., et al. Coverage of antenatal care and intermittent preventive treatment in pregnancy in San, Mali [Internet]. Available from: http://app.core-apps.com/tristar_astmh21/abstract/fe6e6a06-5d57-45ba-b365-a04057a37827	Record not found
Kinde-Gazard D, Vignon Makong J, Kossou HD, Sossa CJ. [Evaluation of the use of insecticide-treated nets and intermittent preventive treatment in three health zones in Benin]. Vol. 105, Bull Soc Pathol Exot. 2012. p. 36–9.	Limited details, not sufficient data to include
Kinyina, A., Lyimo, G., Chamos, S. Impact of community intermittent preventive treatment in pregnancy (C-IPTp) approach on the uptake of IPTp3+: a randomized controlled trial in Karagwe, Tanzania [Internet]. Vol. 13, South Sudan Medical Journal. 2020. p. 175–7. Available from: http://www.southsudanmedicaljournal.com/archive/december-2020/impact-of- community-intermittent-preventive-treatment-in-pregnancy-c-iptp-approach-on-the-uptake-of-iptp3-a-randomized- controlled-trial-in-karagwe-tanzania.html	Used mobile nurses instead of community health workers
Kpormegbe SK, Ahorlu CK. The role of community participation in intermittent preventive treatment of childhood malaria in southeastern Ghana [Internet]. Vol. 48, Ghana Medical Journal. 2014. p. 58–65. Available from: https://lstmed.idm.oclc.org/login?url=https://search.ebscohost.com/login.aspx?direct=true&db=lhh&AN=20143313287&site =ehost-live&scope=site	Children as study population
Kweku M, Webster J, Adjuik M, Abudey S, Greenwood B, Chandramohan D. Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial [Internet]. Vol. 4, PloS one. 2009. p. e7256. Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00731843/full	Children as study population
Leke RGF, Taylor DW. The use of intermittent preventive treatment with sulfadoxine-pyrimethamine for preventing malaria in pregnant women [Internet]. Vol. 53, Clinical Infectious Diseases. 2011. p. 231-233 PMID 21765071. Available from: http://cid.oxfordjournals.org/content/53/3/231.full.pdf+html	Not community intervention of IPTp meeting eligibility criteria
Liberia M of H. Malaria control and prevention through partnership. Liberia Global Fund Proposal Round 3 [Internet]. 2003 Jan. Available from: http://www.theglobalfund.org/grantdocuments/3LBRM_668_0_full.pdf	Record not found
Mahama IY. Community based study of the coverage of intermittent preventive treatment amongst pregnant women in a rural area of southern Malawi [Thesis]. 2004.	Data captured in the review from other publications
Manzi F, Hutton G, Schellenberg J, Tanner M, Alonso P, Mshinda H, et al. From strategy development to routine implementation: the cost of Intermittent Preventive Treatment in Infants for malaria control [Internet]. Vol. 8, BMC health services research. 2008. p. 165. Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00650155/full	Children as study population
Mbaibardoum, N., Baggar, A., Moyreou, D., et al. Evaluation of the contribution of community health workers (CHWs) in improving health facility attendance, particularly for timely ANC attendance and IPTp services, in six districts in the provincial health delegation of the eastern Logone in Chad [Internet]. Vol. 101, American Journal of Tropical Medicine and Hygiene. p. 127.	Conference abstract, insufficient details
Mbonye AK, Bygbjerg I, Magnussen P. Intermittent preventive treatment of malaria in pregnancy: a community-based delivery system and its effect on parasitemia, anemia and low birth weight in Uganda. Vol. 12, International Journal of Infectious Diseases. 2008. p. 22-29 PMID 17526422.	Data captured in the review from other publications
Mbonye AK, Bygbjerg IC, Magnussen P. A community-based delivery system of intermittent preventive treatment of malaria in pregnancy and its effect on use of essential maternity care at health units in Uganda [Internet]. Vol. 101, Transactions of the Royal Society of Tropical Medicine and Hygiene. 2007. p. 1088-1095 PMID 17822729. Available from: http://dx.doi.org/10.1016/j.trstmh.2007.06.017	Data captured in the review from other publications
Mbonye AK, Bygbjerg IC, Magnussen P. Intermittent preventive treatment of malaria in pregnancy: a new delivery system and its effect on maternal health and pregnancy outcomes in Uganda [Internet]. Vol. 86, Bulletin of the World Health Organization. 2008. p. 93-100 PMID 18297163. Available from: http://www.who.int/bulletin/volumes/86/2/07- 041822/en/index.html	Data captured in the review from other publications
Mbonye AK, Bygbjerg IC, Magnussen P. Prevention and treatment practices and implications for malaria control in Mukono District Uganda [Internet]. Vol. 40, Journal of Biosocial Science. 2008. p. 283-296 PMID 17761006. Available from: http://journals.cambridge.org/action/displayAbstract?aid=1660232	Not community intervention of IPTp meeting eligibility criteria
Mbonye AK, Schultz HK, Bygbjerg IC, Magnussen P. Effect of a community-based delivery of intermittent preventive treatment of malaria in pregnancy on treatment seeking for malaria at health units in Uganda [Internet]. Vol. 122, Public Health. 2008. p. 516-525 PMID 18358506. Available from: http://dx.doi.org/10.1016/j.puhe.2007.07.024	Data captured in the review from other publications

Mbuagbaw L, Medley N, Darzi AJ, Richardson M, Habiba Garga K, Ongolo-Zogo P. Health system and community level interventions for improving antenatal care coverage and health outcomes. Vol. 2015, Cochrane Database Syst Rev. 2015. P. Cd010994.	Review, not an original research study
McKenna, A., Tholandi, M., Oseni, L., et al. Bringing innovation to malaria in pregnancy through community engagement in Sub Saharan Africa [Internet]. Available from: http://mwc-2018.p.asnevents.com.au/days/2018-07-03/abstract/51713	Conference abstract, insufficient details
Morgah K, Mbalbardoum N. Improving intermittent preventive treatment for pregnant women (IPTp) coverage in 5 districts in Chad (Doba, Bebedjia, Bodo and Beboto) and Kribi district in Cameroon. Available from: https://www.astmh.org/ASTMH/media/2017-Annual-Meeting/ASTMH-2017-Abstract-Book.pdf	Conference abstract, insufficient details
Msyamboza K, Kazembe P, Brabin B. New approaches to improve coverage and compliance of antimalarial treatment for pregnant women in rural Africa: Community based distribution of SP in pregnancy in Chikwawa, Malawi. 2005.	Data captured in the review from other publications
Mubyazi GM. Economic and other contextual determinants of acceptability and practicability of intermittent preventive treatment for malaria during pregnancy (IPTp) in Tanzania. Case of Mkuranga and Mufindi Districts [Thesis]. 2010.	Not community intervention of IPTp meeting eligibility criteria
Mubyazi GM. Perceived and real costs of antenatal care seeking and their implications for women's access to intermittent preventive treatment of malaria in pregnancy in rural Tanzanian districts [Internet]. Vol. 1, SM Journal of Public Health and Epidemiology. 2015. p. 1009. Available from: http://smjournals.com/index.php/public-health-epidemiology/article/view/168/56	Not community intervention of IPTp meeting eligibility criteria
Mucavele EJ, Torres N. Barriers and facilitators to the acceptability of intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP). In American Journal of Tropical Medicine and Hygiene; 2022. p. 492. Available from: https://www.astmh.org/getmedia/65cc0d8d-1208-4d9a-9f77-734d40de4c02/ASTMH-2022-Annual-Meeting-Abstract-Book.pdf	Data captured in the review from other publications
Munthali JK. Building capacity to accelerate IPTp uptake through the adoption of 2012 WHO IPTp guidance in Malawi [Internet]. Vol. 95, American Journal of Tropical Medicine and Hygiene. p. 122–122.	Conference abstract, insufficient details
Munthali, J., Chinkhumba, J., Chibwana, A., et al. Factors affecting the delivery of community based intermittent preventive treatment of malaria in pregnancy: Perspectives of health workers and beneficiaries in Nkhatabay and Ntcheu districts in Malawi [Internet]. Vol. 103, American Journal of Tropical Medicine and Hygiene. p. 73.	Conference abstract, insufficient details
Munthali, J., Kaunda, E., Wright, K., et al. Sustaining IPTp 3 uptake in Malawi through a health systems approach [Internet]. Vol. 103, American Journal of Tropical Medicine and Hygiene. p. 213.	Conference abstract, insufficient details
Munthali, J.K., Hall, T. Accelerating IPTp3 Uptake in Malawi [Internet]. Vol. 99, American Journal of Tropical Medicine and Hygiene. p. 120–1.	Conference abstract, insufficient details
Mutseyekwa F, Mandigo R, Mashiza S, Mukuzunga M, Grand Z, Uzande C, et al. Assessment of facilitators and barriers to achieving the target IPTp Mutasa District, Manica land Province, Zimbabwe: a formative assessment [Internet]. Available from: http://www.astmh.org/annual-meeting/2017-abstract-book-and-final-program	Conference abstract, insufficient details
Mutulei ACN. Factors influencing the uptake of intermittent preventive treatment for malaria in pregnancy: Evidence from Bungoma East District, Kenya [Internet]. Vol. 1, American Journal of Public Health Research. 2013. p. 110–23. Available from: http://pubs.sciepub.com/ajphr/1/5/2/	Not community intervention of IPTp meeting eligibility criteria
Nct. Assessing the Effectiveness of Community Delivery of Intermittent Preventive Treatment in Pregnancy (IPTp) in Malawi [Internet]. https://clinicaltrials.gov/show/NCT03376217. 2017. Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01566789/full	Data captured in the review from other publications
Nct. Community-based Screening and Treatment of Malaria in Pregnancy: a Cluster-randomized Trial [Internet]. https://clinicaltrials.gov/show/NCT01941264. 2013. Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01590461/full	Data captured in the review from other publications
Nct. Different Approaches for Delivery of IPT in Pregnancy in Burkina Faso [Internet]. https://clinicaltrials.gov/show/NCT00494416. 2007. Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01591857/full	Limited details, not sufficient data to include
Nct. Intermittent Preventive Treatment (IPTc) and Home Based Management of Malaria (HMM)in The Gambia [Internet]. https://clinicaltrials.gov/show/NCT00944840. 2009. Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02034629/full	Children as study population

Nct. New Approaches to Improve Coverage and Compliance of Antimalarial Treatment for Pregnant Women in Rural Africa [Internet]. https://clinicaltrials.gov/show/NCT00730366. 2008. Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01520091/full	Not community intervention of IPTp meeting eligibility criteria
Nct. Strategies to Increase Antenatal Iron and Folic Acid Supplementation and Malaria Prophylaxis [Internet]. https://clinicaltrials.gov/show/NCT04250428. 2020. Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02079943/full	Not community intervention of IPTp meeting eligibility criteria
NCT00118027. A New Approach to Deliver Malaria Preventions to Pregnant Women at a Community Level in Uganda [Internet]. 2005. Available from: https://clinicaltrials.gov/show/NCT00118027	Data captured in the review from other publications
NCT03600844. Evaluating the Effects of Community Delivery of Malaria Intermittent Preventive Treatment on Pregnant Women and Babies [Internet]. 2018. Available from: https://clinicaltrials.gov/show/NCT03600844	Limited details, not sufficient data to include
Ngindu A, Ontiri S, Ndirangu G, Barasa B, Nyapada E, Omoit D, et al. Improving early antenatal care (ANC) attendance and IPT uptake through community health volunteers (CHVS) [Internet]. Available from: http://www.astmh.org/annual-meeting/2017-abstract-book-and-final-program	Conference abstract, insufficient details
Ngindu A. Use of community health workers to improve pregnancy outcomes in Kenya [Internet]. Available from: http://malariamatters.org/jhpiego-at-mim2013-use-of-community-health-workers-to-improve-pregnancy-outcomes-in-kenya/	Conference abstract, insufficient details
Nwogu-Ikojo, L.E. Malaria in pregnancy (MiP): assessing Communities' response to community SST (CSST) carried out by CHW [Internet] [Thesis]. 2018. Available from: https://uhdspace.uhasselt.be/dspace/bitstream/1942/26944/1/d78e8fec-cd00-437f-9a37-65c9bffe1d0c.pdf	Data captured in the review from other publications
Odero NA, Samuels AM, Odongo W, Abong'O B, Gimnig J, Otieno K, et al. Community-based intermittent mass testing and treatment for malaria in an area of high transmission intensity, western Kenya: development of study site infrastructure and lessons learned [Internet]. Vol. 18, Malaria journal. 2019. Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02003291/full	Not community intervention of IPTp meeting eligibility criteria
Odjidja, A. E, Kwanin, C. Prevention of malaria in pregnancy among pastorialists in a humanitarian setting: an exploratory study of ambulatory service delivery models for administering prophylaxis [Internet]. Vol. 113, Transactions of the Royal Society of Tropical Medicine and Hygiene. p. S192. Available from: https://doi.org/10.1093/trstmh/trz090_Poster_Abstracts_Wednesday	Not community intervention of IPTp meeting eligibility criteria
Oele E. Health system strengthening [Internet]. Vol. 95, American Journal of Tropical Medicine and Hygiene. p. 120–120.	Conference abstract, insufficient details
Okedo-Alex IN, Akamike IC, Alo CN, Agu AP, Nzeh CB, Ndukwe CD, et al. Reaching the unreached: effectiveness and satisfaction with community-directed distribution of sulfadoxine-pyrimethamine for preventing malaria in pregnancy in rural south-east, Nigeria. Malaria Journal [Internet]. 2020;19(394). Available from: https://lstmed.idm.oclc.org/login?url=https://search.ebscohost.com/login.aspx?direct=true&db=lhh&AN=20203529710&site =ehost-live&scope=site	Outcomes assessed in pregnant women instead of women who had delivered
Onuoha, E. H, Odio, B., Maly, C., et al. Changes in antenatal care (ANC) attendance and uptake of intermittent preventive treatment of malaria in pregnancy (IPTp) after introduction of community-based distribution of IPTp in three local government areas (LGA) in Nigeria [Internet]. Available from: http://app.core-apps.com/tristar_astmh21/abstract/6eb44d9e-28b6-43dd-9c6a-16cceff85950	Conference abstract, insufficient details
Oresanya OB, Ahmadu A, Adesoro O, Maranda L, Morosso D, Maxwell K. An assessment of quality of delivery of seasonal malaria chemoprevention using low literate community health workers in nigeria [Internet]. Vol. 101, American journal of tropical medicine and hygiene. 2019. p. 119-120. Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02076944/full	Children as study population
Orji BC, Brieger WR, Otolorin E, Nwadike J, Bassey EV, Nkanga M. Health system strengthening through community referral in the management of febrile illness in Nigeria [Internet]. Vol. 87, American Journal of Tropical Medicine and Hygiene. p. 386–386. Available from: http://www.astmh.org/Meeting_Archives.htm	Not community intervention of IPTp meeting eligibility criteria
Ortega, A., Kuile T, F., Madanitsa, M., et al. Malaria during pregnancy: effects of IPTp with DP, DPAZ and SP on maternal immune activiation and Plasmodium falciparum clearance [Internet]. Vol. 103, American Journal of Tropical Medicine and Hygiene. p. 189. Available from: https://www.astmh.org/getmedia/71a0e5e6-7c06-48a4-ab47-d50c4ec870a2/ASTMH-2020-Abstract-Book.pdf	Not community intervention of IPTp meeting eligibility criteria

Ouedraogo A, Coulibaly SO, Diarra A, Traore A, Sirima SB, Magnussen P. Different approaches for delivery of intermittent preventive treatment (IPT) to pregnant women in Burkina Faso [Internet]. Vol. 9 (suppl 2), Malaria Journal. p. 33.	Conference abstract, insufficient details
Pactr. Evaluating Handheld Clinical Decision Support Tools to Improve Community-Based Delivery of Reproductive and Pediatric Health Services [Internet]. https://trialsearch.who.int/Trial2.aspx?TrialID=PACTR201402000725372. 2013. Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01868221/full	Not community intervention of IPTp meeting eligibility criteria
Pantoja T, Opiyo N, Lewin S, Paulsen E, Ciapponi A, Wiysonge CS, et al. Implementation strategies for health systems in low-income countries: an overview of systematic reviews [Internet]. Cochrane Database of Systematic Reviews. 2017. Available from: http://dx.doi.org/10.1002/14651858.CD011086.pub2	Review, not an original research study
Pell C, Straus L, Andrew EV, Menaca A, Pool R. Social and cultural factors affecting uptake of interventions for malaria in pregnancy in Africa: a systematic review of the qualitative research [Internet]. Vol. 6, PLoS ONE. 2011. p. e22452 PMID 21799859. Available from: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0022452	Review, not an original research study
Pell CL. Community responses to malaria: interventions in sub-Saharan Africa [Internet] [Thesis]. 2014. Available from: http://dare.uva.nl/record/470959	Not community intervention of IPTp meeting eligibility criteria
Roman E, Andrejko K, Wolf K, Henry M, Youll S, Florey L, et al. Determinants of uptake of intermittent preventive treatment during pregnancy: a review [Internet]. Vol. 18, Malaria Journal. 2019. Available from: https://lstmed.idm.oclc.org/login?url=https://search.ebscohost.com/login.aspx?direct=true&db=lhh&AN=20203306378&site =ehost-live&scope=site	Review, not an original research study
Roman E, Rawlins B, Gomez P, Dineen R, Dickerson A, Brieger B. Scaling up malaria in pregnancy programs: what it takes. The JHPIEGO experience [Internet]. 2008 Jan. Available from: http://www.jhpiego.org/resources/pubs/spJhp2008malaria.pdf	Not community intervention of IPTp meeting eligibility criteria
Ruizendaal E, Schallig H, Scott S, Traore-Coulibaly M, Bradley J, Lompo P, et al. Evaluation of Malaria Screening during Pregnancy with Rapid Diagnostic Tests Performed by Community Health Workers in Burkina Faso. Vol. 97, Am J Trop Med Hyg. 2017. p. 1190–7.	Data captured in the review from other publications
Ruizendaal E, Schallig H, Traore M, Lompo P, Magloire NH, Traore O, et al. Malaria screening during pregnancy with RDTs performed by community health workers in Nanoro, Burkina Faso [Internet]. Vol. 22, Tropical medicine & international health. 2017. p. 96 Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01419317/full	Limited details, not sufficient data to include
Ruizendaal E. Malaria in pregnancy: in search of tools for improved prevention (2017) [Internet] [Thesis]. 2017. Available from: http://hdl.handle.net/11245.1/bee2681b-939e-4c3a-a751-991ceea6af5c	Data captured in the review from other publications
Sall, B. F, Diaw, S. FB, Gaye, S., et al. Implementation community-based delivery of intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine pyrimethamine in 2020 in the context of the COVID 19 pandemic in Senegal [Internet]. Available from: http://app.core-apps.com/tristar_astmh21/abstract/b53ab7b0-3617-4dbf-8006-78193116a74b	Conference abstract, insufficient details
Schallig H, Ruizendaal E, Traore M, Lompo P, Magloire N, Bradley J, et al. Screening for malaria in pregnancy with rdts by community health workers in nanoro, burkina faso [Internet]. Vol. 97, American journal of tropical medicine and hygiene. 2017. p. 93 Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01462157/full	Did not report on the outcomes of interest (IPTp and ANC).
Sethi R, Seck K, Dickerson A, O'Malley C. A malaria in pregnancy case study: Senegal's successes and remaining challenges for malaria in pregnancy programming [Internet]. 2011 Jan. Available from: http://www.mchip.net/node/731	Limited details, not sufficient data to include
Sirima SB, Cotte AH, Konate A, Moran AC, Asamoa K, Bougouma EC, et al. Malaria prevention during pregnancy: assessing the disease burden one year after implementing a program of intermittent preventive treatment in Koupela District, Burkina Faso [Internet]. Vol. 75, American Journal of Tropical Medicine and Hygiene. 2006. p. 205-211 PMID 16896120. Available from: http://www.ajtmh.org/cgi/content/full/75/2/205	Not community intervention of IPTp meeting eligibility criteria
Solo, R. E, Andriantsitohaina, N. F, Andriarinirina, N. F, et al. Expanding intermittent preventive treatment of malaria in pregnancy (IPTp) through community distribution also increased IPTp uptake through antenatal care visits in three districts of Madagascar [Internet]. Available from: http://app.core-apps.com/tristar_astmh21/abstract/84ead92e-ed71-4b7d-aca8-292f31ba52e1	Conference abstract, insufficient details

Sunguya BF, Mlunde LB, Ayer R, Jimba M. Towards eliminating malaria in high endemic countries: the roles of community health workers and related cadres and their challenges in integrated community case management for malaria: a systematic review [Internet]. Vol. 16, Malaria Journal. 2017. p. 10 PMID PM:28049486. Available from: https://malariajournal.biomedcentral.com/articles/10.1186/s12936-016-1667-x	Review, not an original research study
Tanoh, M. A, Yah, K. C, Agnon, J., et al. Outreach ANC in Côte d'Ivoire leads to improvements in the coverage of IPTp3 in pregnant women [Internet]. Available from: http://app.core-apps.com/tristar_astmh21/abstract/fc272419-0d8a-47cf-98c5-e0ecb1d9ed37	Used mobile nurses instead of community health workers
Tiendrebeogo J, Badolo O, Dodo M, Burke D, Brieger W. Contribution of community-based health workers (CBHWS) to improving prevention of malaria in pregnancy: process for implementing a feasibility study [Internet]. Available from: http://www.astmh.org/annual-meeting/2017-abstract-book-and-final-program	Conference abstract, insufficient details
Tiendrebeogo, J., Badolo, O., Dodo, M., et al. Acceptance of the contribution of community-based health workers (CHBWs) to improving prevention of malaria in pregnancy in Burkina Faso by Health Center Staff [Internet]. Tropical Health Matters. 2018. Available from: http://malariamatters.org/acceptance-of-the-contribution-of-community-based-health-workers-cbhws-to-improving-prevention-of-malaria-in-pregnancy-in-burkina-faso-by-health-center-staff/	Conference abstract, insufficient details
TIPTOP. Delivery of community intermittent preventive treatment in pregnancy in the context of COVID-19 [Internet]. 2020. Available from: https://www.tiptopmalaria.org/wp-content/uploads/2020/04/TIPTOPCOVID-19-Guidelines-Final.pdf	Limited details, not sufficient data to include
White MT, Conteh L, Cibulskis R, Ghani AC. Costs and cost-effectiveness of malaria control interventions - a systematic review [Internet]. Vol. 10, Malaria Journal. 2011. p. 337 PMID 22050911. Available from: http://www.malariajournal.com/content/10/1/337	Review, not an original research study
Wiseman V, Kim M, Mutabingwa TK, Whitty CJ. Cost-Effectiveness Study of Three Antimalarial Drug Combinations in Tanzania [Internet]. Vol. 3, PLoS medicine. 2006. Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00677442/full	Not community intervention of IPTp meeting eligibility criteria
Wolf, K., Alao, M., Onikpo, F., et al. Malaria in pregnancy and antenatal care knowledge, attitudes and intervention coverage in Atlantique Department, Benin [Internet]. Available from: http://app.core-apps.com/tristar_astmh21/abstract/530281f8- f791-4526-b4f4-19e011040ae5	Conference abstract, insufficient details
Wolf, K., Oseni, L., Gomez, P., et al. Understanding malaria in pregnancy service delivery quality in 7 African countries [Internet]. Available from: http://app.core-apps.com/tristar_astmh21/abstract/08a27ea9-1d46-4aaa-8948-559e560fa0b8	Conference abstract, insufficient details
Wolfe EB, Parise ME, Haddix AC, Nahlen BL, Ayisi J, Misore A, et al. Cost-effectiveness of sulfadoxine-pyrimethamine for the prevention of malaria-associated low birth weight [Internet]. Vol. 64, American Journal of Tropical Medicine and Hygiene. 2001. p. 178-186 PMID 11442215. Available from: http://www.ajtmh.org/cgi/reprint/64/3/178	Modeling cost analysis

References

1. Gutman JR, Stephens DK, Tiendrebeogo J, et al. A cluster randomized trial of delivery of intermittent preventive treatment of malaria in pregnancy at the community level in Burkina Faso. *Malar J* 2020; **19**(1): 282.

2. Rubenstein BL, Chinkhumba J, Chilima E, et al. A cluster randomized trial of delivery of intermittent preventive treatment of malaria in pregnancy at the community level in Malawi. *Malar J* 2022; **21**(1): 195.

3. Consortium C. Community-based Malaria Screening and Treatment for Pregnant Women Receiving Standard Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: A Multicenter (The Gambia, Burkina Faso, and Benin) Cluster-randomized Controlled Trial. *Clin Infect Dis* 2019; **68**(4): 586-96.

4. González R, Manun'Ebo MF, Meremikwu M, et al. The impact of community delivery of intermittent preventive treatment of malaria in pregnancy on its coverage in four sub-Saharan African countries (Democratic Republic of the Congo, Madagascar, Mozambique, and Nigeria): a quasi-experimental multicentre evaluation. *Lancet Glob Health* 2023; **11**(4): e566-e74.

5. Gies S, Coulibaly SO, Ky C, Ouattara FT, Brabin BJ, D'Alessandro U. Community-based promotional campaign to improve uptake of intermittent preventive antimalarial treatment in pregnancy in Burkina Faso. *Am J Trop Med Hyg* 2009; **80**(3): 460-9.

6. Okeibunor JC, Orji BC, Brieger W, et al. Preventing malaria in pregnancy through community-directed interventions: evidence from Akwa Ibom State, Nigeria. *Malar J* 2011; **10**: 227.

 Wangalwa G, Cudjoe B, Wamalwa D, et al. Effectiveness of Kenya's Community Health Strategy in delivering community-based maternal and newborn health care in Busia County, Kenya: non-randomized pre-test post test study. *Pan Afr Med J* 2012; **13 Suppl 1**(Suppl 1): 12.

8. Msyamboza K, Senga E, Tetteh-Ashong E, Kazembe P, Brabin BJ. Estimation of effectiveness of interventions for malaria control in pregnancy using the screening method. *Int J Epidemiol* 2007; **36**(2): 406-11.

9. Ndyomugyenyi R, Tukesiga E, Katamanywa J. Intermittent preventive treatment of malaria in pregnancy (IPTp): participation of community-directed distributors of ivermeetin for onchocerciasis improves IPTp access in Ugandan rural communities. *Trans R Soc Trop Med Hyg* 2009; **103**(12): 1221-8.

10. Mbonye AK, Magnussen P, Bygbjerg IB. Intermittent preventive treatment of malaria in pregnancy: the effect of new delivery approaches on access and compliance rates in Uganda. *Trop Med Int Health* 2007; **12**(4): 519-31.

11. Orobaton N, Austin AM, Abegunde D, et al. Scaling-up the use of sulfadoxine-pyrimethamine for the preventive treatment of malaria in pregnancy: results and lessons on scalability, costs and programme impact from three local government areas in Sokoto State, Nigeria. *Malar J* 2016; **15**(1): 533.

12. Kayentao K, Ghosh R, Guindo L, et al. Effect of community health worker home visits on antenatal care and institutional delivery: an analysis of secondary outcomes from a cluster randomised trial in Mali. *BMJ Glob Health* 2023; **8**(3).

13. Gebeyehu FG, Geremew BM, Belew AK, Zemene MA. Number of antenatal care visits and associated factors among reproductive age women in Sub-Saharan Africa using recent demographic and health survey data from 2008-2019: A multilevel negative binomial regression model. *PLOS Glob Public Health* 2022; **2**(12): e0001180.

14. van Eijk AM, Hill J, Larsen DA, et al. Coverage of intermittent preventive treatment and insecticide-treated nets for the control of malaria during pregnancy in sub-Saharan Africa: a synthesis and meta-analysis of national survey data, 2009-11. *Lancet Infect Dis* 2013; **13**(12): 1029-42.

15. Mbonye AK, Bygbjerg I, Magnussen P. Intermittent preventive treatment of malaria in pregnancy: evaluation of a new delivery approach and the policy implications for malaria control in Uganda. *Health Policy* 2007; **81**(2-3): 228-41.

16. Okedo-Alex IN, Akamike IC, Nwafor JI, et al. Community Malaria Knowledge, Experiences, Perceived Roles, and Acceptability of Community-Directed Distribution of Intermittent Preventive Therapy for Pregnancy in Rural Southeast Nigeria. *J Parasitol Res* 2022; **2022**: 8418917.

17. Burke D, Tiendrebeogo J, Emerson C, et al. Community-based delivery of intermittent preventive treatment of malaria in pregnancy in Burkina Faso: a qualitative study. *Malar J* 2021; **20**(1): 277.

Alonso Y, Lusengi W, Manun'Ebo MF, et al. The social dimensions of community delivery of intermittent preventive treatment of malaria in pregnancy in Madagascar, Mozambique, Nigeria and the Democratic Republic of the Congo. *BMJ Glob Health* 2022; 7(11).
 Enguita-Fernàndez C, Alonso Y, Lusengi W, et al. Trust, community health workers and delivery of intermittent preventive treatment

of malaria in pregnancy: a comparative qualitative analysis of four sub-Saharan countries. *Glob Public Health* 2021; **16**(12): 1889-903. 20. Okedo-Alex IN, Akamike IC, Alo CN, et al. Reaching the unreached: effectiveness and satisfaction with community-directed

distribution of sulfadoxine-pyrimethamine for preventing malaria in pregnancy in rural South-East, Nigeria. *Malar J* 2020; **19**(1): 394. 21. Mbonye AK, Bygbjerg I, Magnussen P. Intermittent preventive treatment of malaria in pregnancy: a community-based delivery system

and its effect on parasitemia, anemia and low birth weight in Uganda. *Int J Infect Dis* 2008; **12**(1): 22-9.